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Abstract
Several clinical studies have demonstrated that intrauterine growth restriction (IUGR)
offspring, faced with a nutritional mismatch postpartum, have an increased risk of developing
the metabolic syndrome. The maternal protein restriction (MPR) rat model has been
extensively studied to investigate the adverse effects of a nutritional mismatch in postnatal
life of IUGR offspring. Previous studies have demonstrated that MPR leads to impaired
function of the liver, an important metabolic organ for lipid and glucose homeostasis along
with drug catabolism. However the underlying mechanisms which predispose these offspring
to the metabolic syndrome remain elusive. In the following studies, low protein diet during
pregnancy and lactation led to IUGR offspring with decreased liver to body weight ratios,
followed by increased circulating and hepatic cholesterol levels in both sexes at day 21 and
exclusively in the male offspring at day 130. These long-term increases in cholesterol levels
mirrored decreases in cholesterol 7α-hydroxylase (Cyp7a1), a rate-limiting enzyme that
catabolizes cholesterol to bile acids. This was due, in part, to diminished acetylation and
enhanced methylation of histone H3 [K9,14], markers of chromatin silencing, at the promoter
region of Cyp7a1. It was later demonstrated that these IUGR offspring exhibited increased
molecular markers of hepatic endoplasmic reticulum (ER) stress and insulin resistance
exclusively when they were faced with a nutritional mismatch in postnatal life. Finally, as
cytochrome p450 (Cyp) dependent enzymes reside in the ER of the liver and are the primary
enzymes involved in Phase 1 of drug metabolism, it was relevant to determine whether MPR
lead to long-term alteration in their ability to metabolize drugs (e.g. statins for
hypercholesterolemia). MPR offspring were shown to have an increase in enzymatic activity
of the major drug metabolizing enzymes Cyp3a and Cyp2c. This was postulated to be due, in
part, to transcriptional induction by constitutive androstane receptor. Collectively, these
findings suggest that stable promoter-specific changes to post-translational histone
modifications and elevated ER stress in the liver, are key molecular mechanisms whereby
IUGR offspring receiving a nutritional mismatch in postnatal life develop high cholesterol
and insulin resistance. Moreover, it can be postulated that these offspring require augmented
doses of drugs in order to effectively alleviate these symptoms. This new knowledge would
serve useful in the development of both prevention and management strategies to reduce the
debilitating impact of metabolic diseases in low birth weight babies.
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INTRODUCTION1

A portion of this Introduction has been reproduced (adapted) with permission from: Sohi G, Revesz A,
Hardy DB (2011) Permanent implications of intrauterine growth restriction on cholesterol homeostasis.
Semin Reprod Med 29(3): 246-56.

2

1.1

Cardiovascular Disease

While significant advances in medicine have been made over the past 50 years to
improve overall health, cardiovascular disease (CVD) still remains the leading cause of
premature death worldwide. Without dispute, the risk of developing cardiovascular
disease increases in individuals diagnosed with the metabolic syndrome. For example, a
1998 prospective Québec cardiovascular study has demonstrated that adults with the
metabolic syndrome have a ~18-fold risk of developing CVD compared to adults who do
not exhibit this syndrome1. Moreover, the incidence of metabolic syndrome in Canada is
reaching epidemic proportions, with one in three Canadian family practice patients
between 40 and 60 years of age falling under this criteria2. The World Health
Organization (WHO) has identified hypercholesterolemia and insulin resistance, in
addition to obesity and hypertension as one of the major symptoms characterizing the
metabolic syndrome3, 4. Specifically, WHO criteria for metabolic syndrome include
insulin resistance as identified by type 2 diabetes or impaired fasting glucose and/or
tolerance, alongside any two of the following: high blood pressure (≥140 mm Hg systolic
or ≥90 mm Hg diastolic), high density lipoprotein (HDL) cholesterol <0.9 mmol/L in
men or <1.0 mmol/L in women, plasma triglycerides ≥1.7 mmol/L, BMI >30 kg/m 2 or
urinary albumin excretion rate ≥20 μg/min5. While the criteria for metabolic syndrome
only encompasses low levels of HDL plasma levels, hypercholesterolemia could be due
to high levels of low density lipoprotein (LDL) or HDL levels depending on whether we
are detecting it in the plasma levels of rodents (e.g. mice or rats) or humans. This is
because humans predominantly carry cholesterol in the form of LDL while rodents
predominantly carry cholesterol in the form of HDL6. Therefore, in this thesis
“hypercholesterolemia” is with reference total circulating cholesterol levels.

1.2

Impact

of

Hypercholesterolemia

and

Impaired

Glucose

Tolerance on Cardiovascular Disease
Maintaining normal cholesterol levels and glucose homeostasis is critical for reducing the
risk of developing CVDs. For example, a meta-analysis prospective study, using data
from 58 clinical trials as well as nine cohort studies, indicates that in patients with

3

cardiovascular disease, a 1.8 mM reduction in low density lipoprotein (LDL) cholesterol
by statins from pretreatment concentrations of 4.8 mM resulted in a 17% reduction in
stroke and a 60% reduction in the risk of ischemic heart disease7. While statin therapies
are considered safe and effective, incidences of statin induced skeletal muscle damage
(i.e. rhabdomyolysis) and hepatitis associated liver failure exist in some patients5.
Similarly, individuals with impaired glucose tolerance have been estimated to have twice
the risk for developing cardiovascular disease8. Therefore, targeted treatment of
hyperglycemia, notably by metformin, is considered to be an effective strategy in
preventing cardiovascular disease in diabetic patients9,

10

. However, many individuals

with impaired glucose intolerance and high cholesterol display no symptoms for many
years, resulting in premature mortality due to a failure to receive timely diagnosis and
treatment11-13. Therefore, despite current therapeutic modalities which are aimed to
reduce the incidence of the metabolic syndrome through lifestyle modifications (i.e.
changes in diet and physical activity) and/or pharmacological interventions, CVD still
remains the leading cause of mortality in North America. As a consequence, this places
an enormous human and economic burden on society, where 1 in every 2.9 deaths in the
United States is due to CVD14-17. In order to effectively alleviate the burden of this
pandemic proactive development of strategies which focus on disease prevention prior to
the manifestation of the adverse symptoms are warranted.

1.3

Developmental Origins of Adult Disease

The ‘fetal origins’ or ‘Barker’ hypothesis suggests that adverse maternal events that lead
to impaired fetal and neonatal growth results in offspring that are at a higher risk of
developing chronic diseases in later life (Figure 1.1)18-20. Epidemiological evidence
strongly indicates that adverse events in utero (i.e. maternal hypoxia, undernutrition,
infection, stress) can permanently alter physiological processes leading to the metabolic
syndrome21, 22. As a result, the last two decades have witnessed an increase in clinical and
animal studies focused on understanding the role of the fetal environment in the longterm regulation or ‘programming’ of metabolic functions. Moreover, these studies have
also sought to elucidate the molecular mechanisms involved in the etiology of these
metabolic diseases in adult life. In understanding the role of the perinatal and/or postnatal

4

environment on long-term health, therapeutic intervention strategies can be targeted to
prevent the onset of the metabolic syndrome.
Despite our best efforts, the rates of preterm and low birth weight pregnancies have
increased over the previous two decades in Canada and the United States
(www.marchofdimes.com/peristats)23. Given these trends, it is noteworthy that a majority
of metabolic syndrome related diseases have been linked to adverse events in utero21, 24,
25

. While low birth weight is the most common indicator used in clinical studies to

correlate impaired fetal development and adverse outcomes in adulthood, the nature of
the growth restriction (e.g. asymmetrical vs symmetrical IUGR) may alter this
relationship. For instance, symmetric growth restriction refers to when the entire body is
proportionally small. As a consequence, expert medical evaluation is required to
distinguish whether the symmetric IUGR is due to pathological or normal development
process26. This evaluation is important before a correlation between symmetric IUGR and
adverse postnatal consequences can be investigated. On the contrary, placental
insufficiency predominantly underlies most cases of asymmetric growth restriction,
where the offspring has a normal head dimension but reduced abdominal circumference
and limb size26. It is now well established that asymmetric IUGR has a strong correlation
with increased risk of adverse outcomes in adult life. Lastly, aside from a careful
consideration of the type of IUGR as a predictive indicator of these outcomes in
adulthood, confounding factors also need to be accounted for. Most notably, these
include influence of maternal socioeconomic status27, preexisting maternal CVD risk
factors28, maternal smoking/high blood pressure29,

30

and maternal BMI31-33 on birth

weight and adult diseases.

1.4

Thrifty Phenotype Hypothesis

The postnatal environment can also influence the correlation between IUGR and CVD.
For instance adverse events during development induce fetal adaptations that allow for
optimal survival in a similar predictive environment in postnatal life. However, the
“thrifty phenotype” hypothesis suggests that these adaptations can become maladaptive if
there is a ‘mismatch’ to the predictive environment34,

35

. Clinically, low birth weight

5

offspring that underwent rapid postnatal catch-up growth due to mismatch in their
postnatal environment (i.e. infant formula diets, overnutrition) displayed earlier
indications of glucose intolerance, insulin resistance, dyslipidemia, obesity and higher
death rates due to CVD (Figure 1.1)36-40. In addition, appropriate neonatal growth rates
(i.e. due to breastfeeding) had a lower risk of hypercholesterolemia42, type 2 diabetes43,
obesity44 and CVDs45.

1.5

Clinical

Perspective:

Developmental

Origins

of

Hypercholesterolemia and Impaired Glucose Tolerance
To date, numerous studies have demonstrated a strong inverse association between birth
weight and metabolic risk factors associated with CVD (Figure 1.1)46-49. With respect to
cholesterol, the first study to observe a link between development and subsequent
dyslipidemia was conducted by Forsdahl in 197850. This study detected a significant
positive correlation between poor living conditions in early childhood (based on the
infant mortality rate) with higher cholesterol in men and women aged 35-49 years from
within the same geographical area. In addition, a cohort of this study was also found to
have an increased risk of coronary heart disease51. Similarly, Amendt in 1976 observed
adolescents born to diabetic mothers displayed early symptoms of diabetes including
impaired glucose intolerance52. Since these initial observations, the correlation of fetal
growth to elevated cholesterol levels and glucose intolerance in adult life was popularized
by the work of Barker and colleagues53, 54. Moreover, Barker also demonstrated that a
positive correlation existed between birth weight and increased risk of death from
ischemic heart disease46. Many of the initial clinical data suggest strong support for low
birth weight being linked to an atherogenic lipid profile and type 2 diabetes in adult life
45, 55-57

. However, some studies have indicated some inconsistencies with respect to this

profile and ischemic heart disease58, 59, despite a strong correlation with type 2 diabetes60.
Some have argued that impaired fetal growth, as indicated by low birth weight, does not
necessarily affect adult cholesterol levels enough to have any clinically significant effect
in developing CVD31. These authors further suggested that previous studies
demonstrating strong inverse associations between birth weight and postnatal cholesterol
levels were influenced by a publication bias resulting from inappropriate adjustment for
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current weight and other confounding factors31. In addition, they argue that
socioeconomic status has been demonstrated to have a greater impact on adult lipid levels
when compared to birth weight61.
In light of these arguments, it is still important not to underestimate the role of fetal
development in the programming of adult cholesterol metabolism, type 2 diabetes and
ischemic heart disease. First and foremost, a majority of studies use birth weight as an
indicator of restricted fetal growth, although this may not be the best marker of fetal
development. Secondly, while different in utero conditions (i.e. undernutrition, hypoxia,
excess glucocorticoids) can result in low birth weight, it does not necessarily mean that
all of these conditions impair the development of organs (i.e. liver, small intestine) in a
similar manner that is critical to cholesterol homeostasis. Interestingly, as the liver is a
major site of cholesterol regulation, it has been demonstrated that abdominal
circumference at birth, which provides an indirect measure of liver growth, has a stronger
correlation with adult dyslipidemia than birth weight55. The next generation of follow up
studies need to better incorporate in utero biomarkers for the earlier detection of
abnormal liver development. Thirdly, care must be taken while drawing conclusions from
meta analysis studies investigating links between birth weight and cholesterol levels later
in life, as many studies used in the meta analysis examine cholesterol levels at different
postnatal timepoints31, 58. This can influence the strength of the correlation because as one
ages, adaptive responses to maintain cholesterol levels early in life may become
maladaptive. Finally, these meta-analysis include studies which have variations with
respect to gender, genetic makeup or postnatal environment, all of which may also further
diminish this correlation62. Since twins experience a relatively similar environment
during fetal and postnatal development, clinical studies involving twins would be less
prone to the effects of the previously discussed factors. In addition, monozygotic twins
would be particularly useful, as their genetic variability would be minimal. However,
there has been an issue concerning the use of twins in linking birth weight to metabolic
disease given their low statistical size63, 64. Future clinical studies should address some of
the highlighted shortcomings from earlier studies in order to better understand the
implications of impaired development on long-term cholesterol regulation and ischemic
heart disease. Given the time involved for these follow-up studies, animal models are
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beneficial in aiding our understanding of the molecular mechanisms involved in the
developmental origins of long-term cholesterol and glucose homeostasis.
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IN UTERO INSULTS

LOW BIRTH
WEIGHT

Rapid Postnatal
Catch-up Growth

THRIFTY PHENOTYPE

HYPERCHOLESTEROLEMIA

GLUCOSE INTOLERANCE
ADULTHOOD
METABOLIC
SYNDROME

CARDIOVASCULAR
DISEASE

Figure 1.1: Developmental origins of adult disease schematic. Several in utero insults
leading to low birth weight offspring can increase the risk of metabolic syndrome in
adulthood and subsequent risk of cardiovascular disease. This risk is further increased if
the low birth weight offspring undergo rapid postnatal catch-up growth, leading to a
thrifty phenotype.
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1.6

Animal

Models

in

the

Developmental

Origins

of

Hypercholesterolemia and Impaired Glucose Tolerance
Even before the formulation of the Barker’s hypothesis, animal models have successfully
demonstrated that impaired fetal development compromises the ability of the offspring in
regulating cholesterol or glucose in adult life. For example, premature weaning in rats
was demonstrated to result in increased serum cholesterol levels and an inability to
respond to a cholesterol challenge in the adult offspring65,

66

. In addition, studies in

guinea pigs have indicated that premature weaning leads to cholesterol dysregulation at
postnatal day 10 and day 4567. This was attributed to decreases in cholesterol 7αhydroxylase (Cyp7a1) activity, the rate limiting enzyme involved with the conversion of
cholesterol to bile acids. Furthermore, sows with pharmacological induced gestational
diabetes have been associated with offspring that exhibit impaired insulin response and
glucose intolerance in neonatal life68. While these studies suggest that perturbations in
fetal and neonatal life can have short-term consequences on cholesterol and glucose
homeostasis, there are limited studies that address the effects of in utero insults on longterm programming of glucose and cholesterol homeostasis. In addition, the long-term
impact of factors that contribute to the “Thrifty Phenotype” in these offspring has not
been elucidated. The most notable intrauterine insults associated with impaired fetal
development are decreases in nutrients and oxygen delivery to the fetus. Therefore, it is
important to delineate the contributions of both nutrition and hypoxia to long-term
metabolic diseases.

1.6.1

Effects of Hypoxia on Long-term Cholesterol and Glucose
Homeostasis

Using the rat as a model, maternal hypoxia during pregnancy has been demonstrated to
lead to IUGR, impaired liver development, cardiac remodeling, diastolic dysfunction and
increased sensitivity to ischemia in adulthood69,

70

. While this model is an excellent

model to study the fetal origins of CVD, the effect of maternal hypoxia on components of
the metabolic syndrome preceding CVD (e.g. hypercholesterolemia) are less understood.
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Recent evidence suggests that maternal hypoxia derived offspring have impaired ability
to regulate cholesterol leading to hypercholesterolemia when administered a high-fat
dietary challenge at 10 months of age71. Moreover, maternal hypoxia during pregnancy
led to increased risk of developing CVD, as there were indications of early pathological
appearances of atherosclerosis in adult offspring71. Surgical ligation of the uterine artery
(gestational day 19-21) in rats is a commonly used method to induce IUGR by reducing
uteroplacental blood flow. This method has been previously demonstrated to decrease βcell mass and impair glucose tolerance by 7 weeks of age72. At 9 weeks of age the IUGR
offspring display hyperlipidemia and become insulin resistant73. Apart from reducing
oxygen supply, decreasing blood flow by uterine ligation also reduces the transfer of
amino acids, glucose and insulin. Therefore, it becomes difficult to delineate the direct
effect of hypoxia on long-term disease risks in this experimental model of hypoxia.
Placing rats in hypoxic chambers during gestation is usually the alternate approach
undertaken to circumvent this issue69,

70

. Typically, rats are placed under an enclosed

hypoxic chamber with an oxygen concentration of 10% during the last 6 days of
gestation69, 70, 74. Interestingly, prenatal hypoxia independent of undernutrition has been
demonstrated to promote molecular markers of insulin resistance and increased cardiac
susceptibility to ischemia injury69,

74

.

However, recent work in our laboratory has

demonstrated that this maternal hypoxia model leads to decreases in circulating glucose,
but no change in cholesterol in 12 month offspring75. Additional work is required to
elucidate the molecular mechanisms behind this observation.

1.6.2

Maternal

Iron

Restriction

in

Rodents

on

Long-term

Cholesterol and Glucose Homeostasis
Given that ~50% of pregnant women are iron deficient and that maternal anemia is linked
to abnormalities in birth weight76, animal models of iron restriction have been utilized to
explore the link between impaired fetal development and long-term diseases. In rats,
maternal iron restriction has been demonstrated to lead to decreases in fetal weight and
plasma cholesterol levels, but an increase in fetal hepatic cholesterol77. In addition, this
corresponded with reduced expression of fetal hepatic expression of key cholesterol
catabolism (i.e. Cyp7a1) and triglyceride synthesis (i.e. Srebp1-c) genes77. Consequently,
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there was a reduction in the hepatic expression of Srebp1-c downstream transcriptional
target genes Fatty acid synthase (Fas) and Acetyl-coenzyme A carboxylase- (Acc)79.
Interestingly, maternal iron restriction did not alter plasma cholesterol levels and actually
improved glucose tolerance in the offspring by three months78. This suggests that iron
restriction in utero has short-term effects on fetal liver function which may be corrected
with restoration of maternal iron postpartum. This recovery in function is likely to be due
to the highly plastic nature of the rat liver during the first three weeks of neonatal life79.
However, it still remains possible that maternal iron restriction may alter hepatic
cholesterol and glucose regulation long-term (>3 months). In order to accurately
extrapolate these findings to assess the impact of maternal iron deficiency on long-term
liver function in humans, an iron deficient diet should continue to be administered for the
first three weeks of postnatal life in these rat offspring, since in rodents liver
differentiation develops late in gestation with a large portion of it occurring in postnatal
life. In contrast, liver differentiation in humans already occurs by early to midgestation80. Therefore, at birth the rat liver is ‘less’ mature and has greater plasticity than
the human liver. This makes the rat liver more susceptible to further insult or recovery
during early neonatal life

1.6.3

Effects of Low Protein Diet on Long-term Cholesterol and
Glucose Homeostasis

While iron restriction in pregnancy has been demonstrated to lead to IUGR and elevated
fetal cholesterol levels77, the maternal protein restriction (MPR) rat model is one of the
most widely used animal models to investigate the correlation between IUGR and adult
diseases. Since amino acids play a critical role in fetal growth81, this MPR model is a
relevant model to study the fetal origins of adult diseases. Furthermore, as placental
insufficiency in humans can produce protein deficiency in the fetus82, this MPR model
shares features in common with IUGR, which represents 8% of newborns19, 20. Studies of
Wistar rats have demonstrated that a MPR diet (8% protein vs 20% protein control)
during gestation and lactation results in decreased birth weight (asymmetrical IUGR83),
and permanently reprograms the functions of various organs including the pancreas84-86,
muscle87, adipose tissue88 and liver89-92. In the liver, reduced maternal dietary protein is
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associated with alterations in hepatic glucose output, decreased glucagon receptor and
glucokinase expression, along with increases in hepatic lobular volume90. As a result of
MPR on the function of these organs, the offspring exhibit increased visceral fat88,
symptoms of type 2 diabetes93, 94, and hypertension95, 96 in adulthood. Given that these
symptoms characterize the metabolic syndrome97 which substantially increases the risk
for CVD1, this MPR model is very useful to study the fetal programming of CVD.
However, the role of MPR on circulating cholesterol, another important clinical risk
factor characterizing the metabolic syndrome97, remains elusive.
There is growing evidence that individual amino acids may be as important as the overall
levels of macronutrients in determining size at birth and postnatal disease risk. For
example, supplementing a MPR diet with glycine alone can prevent postnatal
hypertension98. Others have demonstrated that taurine supplementation to the MPR diet
during

pregnancy

and

lactation

restores

islet

proliferation

and

pancreatic

vascularization99, 100. Future research on the role of micronutrients during development on
the risk of postnatal diseases is anticipated with great interest. For a review on the role of
macronutrients in the developmental origins of health and disease, please see a review
article previously published by our laboratory101.
Collectively, animal models of IUGR provide further support for the hypothesis that
impaired development due to various maternal deficiencies can lead to impaired glucose
and cholesterol homeostasis in adulthood77, 85, 102-104. These deficiencies in humans and
animals can include hypoxia71, diminished protein105, caloric restriction106, excess
glucocoritcoids107,

108

, infections109 or deficiencies in the microenvironment including

specific amino acids, vitamins and minerals78, 98, 110-112. Although the correlation between
impaired development and the risk of developing chronic disease in adult life is
undoubtedly

strong,

the

molecular

mechanisms

behind

pathophysiological processes are only beginning to be elucidated.

programming

of
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1.7

Molecular Mechanisms Underlying the Early Programming of
Metabolic Syndrome

Regardless of the type of in utero insult, animal models comprehensively demonstrate
that the long-term regulation of cholesterol and glucose homeostasis is permanently
altered in IUGR offspring. However, the molecular mechanisms underlying these events
are only beginning to be uncovered.

1.7.1

Transcriptional

Mechanisms

Underlying

the

Early

Programming of Metabolic Syndrome
Without question, understanding the role of transcription factors in this process will
provide us with specific drug targets for the prenatal and postnatal prevention of these
adult diseases. Nuclear receptors represent the largest family of transcription factors
found in metazoans, binding to steroid hormones, fat-soluble vitamins, along with
oxysterols and bile acids from the diet113. Although the roles of many nuclear receptors
are well defined, very little is known about their function in fetal programming. As
mentioned previously, a subset of nuclear hormone receptors, namely the Liver X
Receptors (LXRα and LXR), are important mediators of cholesterol and glucose
homeostasis in the adult by serving as important transcription factors113,

114

. Both

receptors share 77% homology and heterodimerize with the Retinoid X Receptor (RXR)
to activate a wide variety of downstream target genes important for glucose synthesis and
uptake, and cholesterol metabolism and efflux113, 114. The LXR/RXR heterodimer can be
activated by both RXR ligands (i.e. retinoids) and LXR ligands (i.e. oxysterols)113. Upon
ligand activation there is a recruitment of coregulators at the LXRE site of LXR target
genes115. The LXRα isoform is highly expressed in the liver but is also abundant in
macrophages, the intestine, muscle, adipose and kidney, while LXRβ is ubiquitously
expressed113. One of the main functions for LXRs is activating the expression of
cholesterol 7a-hydroxylase (Cyp7a1), the rate-limiting enzyme for the conversion of
cholesterol to bile acids. Studies where adult mice were fed a diet 100 times greater than
their normal daily cholesterol intake found that they did not form atherosclerotic
lesions116. This was demonstrated to be due to an LXRα-mediated increase in the
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expression of Cyp7a1116. However, mice deficient in LXRa lose the capacity to
catabolize dietary cholesterol, via decreases in the expression of Cyp7a1, along with
impairments in sterol and fatty acid synthesis117. These studies implicate the important
role of LXR in cholesterol homeostasis. The LXR knockout mouse does not exhibit
any alterations in bile acid metabolism118, however mice deficient in both LXR and
LXR exhibit a more severe phenotype than LXR null mice alone with respect to
cholesterol dysregulation119. In addition to promoting cholesterol catabolism (i.e.
Cyp7a1), LXR and LXR regulate transcription of a number of other target genes
involved with cholesterol homeostasis, including efflux (ATP-binding cassette
transporters ABCA1, ABCG5 and ABCG8) and high density lipoprotein (HDL)-mediated
reverse transport (apoE, PLTP, CETP)115. Mutations in several of these LXR target genes
have major effects on circulating cholesterol concentrations and upon cardiovascular
disease120. For instance, humans lacking functional ABCA1 exhibit lower circulating
HDL, increased arterial wall thickness, and a 6-fold increased risk for cardiovascular
disease121. In addition, humans or mice deficient in apoE have elevated plasma
cholesterol (LDL), triglycerides, and cardiovascular risk122, 123. More recently, the role of
LXR as an important regulator of glucose homeostasis has been established124.
Specifically, LXR has been found to repress critical genes involved with glucose
production,

including

glucose-6-phosphatase

(G6Pase),

phosphoenolpyruvate

carboxykinase (Pepck) and 11β-hydroxysteroid dehydrogenase-1 (11β-HSD1), and
increased expression of genes involved with glucose uptake, including glucose
transporter 1 and 2125-127. G6Pase and Pepck are genes involved with gluconeogenesis,
while 11β-HSD1 increases glucose production by converting inactive corticosteroids to
their active form (Figure 1.2).
Given that LXR plays a role in both cholesterol113 and glucose114 homeostasis, it is an
attractive candidate for elucidating the molecular mechanisms underlying the etiology of
the metabolic syndrome. To date, few studies have demonstrated links between nutrition,
LXRs and liver function. Our laboratory has recently demonstrated that maternal hypoxia
during pregnancy decreases the expression of hepatic G6Pase in adult offspring due to
repressive changes at the DR-4 LXRE region (-258 to -169) of the rat G6Pase
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promoter75. Both iron restriction and maternal protein restriction have been demonstrated
to lead to decreased fetal LXR77, 128, but less is known about the long-term effects in
postnatal life. Further work on the role of LXR, RXR, and other lipid-sensing nuclear
receptors are warranted to understand the transcriptional mechanisms involved in
cholesterol dysregulation and impaired glucose tolerance.

16

Figure 1.2: Schematic Diagram of LXR and some of its main downstream target genes
involved with fatty acid synthesis, cholesterol homeostasis and glucose homeostasis. + =
positively regulate, - = negatively regulate.
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1.7.2

Epigenetic Mechanisms Underlying the Early Programming
of Metabolic Syndrome

Epigenetics is an important mechanism in regulating the expression patterns of genes in a
site and tissue specific manner in response to insults during development. The term
‘epigenetics’ was coined in 1942 by Conrad Waddington and was defined as ‘the branch
of biology that studies the casual interactions between genes and their products, which
bring the phenotype into being’129. Most recently, Michael K. Skinner has defined
epigenetics as ‘molecular factors and processes around DNA that are mitotically stable
and regulate genome activity independent of DNA sequence’130. Epigenetic mechanisms
essentially influence the long-term expression of a gene by altering the ability of the
transcriptional machinery to interact with the chromatin environment. One way this can
be accomplished is by direct DNA methylation via the addition of a methyl group to CpG
sites on the DNA by members of the DNA methyltransferase family. Traditionally, an
increase in methylation across CpG sites can impair initiation, elongation or termination
of a gene. However, this may not always hold true as is the case with expression of
Insulin-like growth factor-II (Igf-II), which is increased in IUGR offspring due to
increased intragenic methylation131. Animal models have previously demonstrated that a
change in the environment as a result of an abundance or a limitation of nutrients during
the period of development alters the expression of a variety of genes involved with DNA
methylation, including DNA methyltrasnsferases132-134. However, very little is known
about the impact of these alterations in correlation with promoter specific methylation
status and long-term transcription of genes involved with cholesterol and glucose
homeostasis in IUGR offspring135. At the moment, clinical and animal studies are only
beginning to demonstrate alterations in promoter specific methylation patterns of key
genes associated with cholesterol dysregulation and type 2 diabetes in IUGR offspring,
exclusively at an observational level128, 136, 137.
The second major epigenetic mechanism involves influencing the chromatin environment
via a number of post-translational modifications. Chromatin is mainly compromised of
genomic DNA complexed with histone and non-histone proteins. Nucleosomes, the basic
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building bƒtarlocks of chromatin138, are composed of 146 base pairs of DNA wrapped
around two copies each of histones H2A, H2B, H3 and H4 which comprise the histone
octamer12. Histones are subject to a wide variety of post-translational modifications at
over 60 amino acid residues139, including methylation, acetylation, phosphorylation,
ubiquitination and ADP-ribosylation139,

140

. The combinatorial nature of these covalent

modifications reveals a “histone code” 139, 140. This code provides for a regulatory system
that may dictate the transient, as well as long-term, transition between gene silencing or
activation (Figure 1.3). Amongst all the different types of post-translational histone
modifications, acetylation and methylation of lysine and phosphorylation of serine and
threonine residues can be considered as well characterized. This is because their roles
have been exhaustively examined through genome wide mapping studies which were
geared towards detecting correlations between histone modification patterns and specific
states of gene activity141. The effects of other types of post-translational histone
modifications on the overall chromatin structure are poorly understood and are mostly
analyzed at the descriptive level141. Of interest, acetylation and phosphorylation of
histones have a high turnover rate, with a half life of only a few minutes142,

143

. In

contrast, the turnover of histone lysine methylation is much slower and is similar to that
of the entire histone (~1.3 days)144. In addition, the greater the degree of methylation (i.e
mono, di or tri-methylation), the greater the half-life and more stable the chromatin
state144,

145

. Therefore, amongst all of the well characterized post-translational histone

modifications, the tri-methylation of histone at lysine residues can be regarded as most
suited towards maintaining long-term gene transcription140,

146-149

. Genes linked to

cholesterol and glucose homeostasis can be upregulated or repressed depending on
changes to the availability and demand of these two products in the body. Therefore, their
promoter regions are expected to facultatively change from euchromatin to
heterochromatin states, in order for transcription factors and co-regulators to
appropriately access the region and exert their transcriptional effects. Therefore, amongst
all the possible histone lysine residues which are known to be tri-methylated, focus
should be aimed at those residues which have been previously observed to occur at both
facultative heterochromatin as well as euchromatin regions of the genomic DNA150-158.
Furthermore, careful consideration should be given on determining which specific lysine
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residue on the histones is tri-methylated. This is because depending on the type and
location of the amino acid residue undergoing the posttranslational histone modification,
one can observe either an increase or a decrease in gene transcription. For instance, an
increase in the levels of tri-methylation at Histone H3 at lysine 4 and 36 is associated to
be linked to active transcription. Conversely, if the increase in tri-methylation were to
occur at Histone H3 lysine at 9 and 27, it would be associated with transcriptional
repression159.
It is important to realize that the different prenatal insults which lead to IUGR offspring
seem to have both common and distinct adaptive responses initiated via epigenetic
mechanisms. Therefore IUGR offspring derived from different insults may differ or be
similar due to global, tissue, or site-directed epigenetic modifications. To date, there is
very little known about the epigenetic alterations associated with expression of target
genes in the liver throughout normal and abnormal fetal and postnatal development91, 92,
160

. Given that LXR has an important role in regulating transcription of genes linked to

cholesterol homeostasis113, it becomes important to evaluate the underlying role of
epigenetic

mechanisms

(i.e.

DNA

methylation

and

posttranslational

histone

modifications) on regulating the long-term transcription of LXR and its target genes in
an animal model of IUGR. However, there is limited knowledge about the
posttranslational histone modifications which alter the activation of LXR target genes.
One study in chick embryonic hepatocytes has demonstrated that LXR agonists increase
the transcription of ACCα via increased LXR binding to the LXRE within the 5’
upstream region of ACCα along with enhanced acetylation of Histone H3161. In vitro
studies by Yu et al. have demonstrated that the LXR mediated transcriptional activation
of the FAS gene was associated with enriched Histone H3 and H4 acetylation at the
LXRE within 30 minutes of ligand addition162. While these studies suggest that LXR
target genes are subject to regulation by posttranslational histone modifications, little is
known about the epigenetic alterations associated with expression of hepatic LXR target
genes throughout normal or abnormal fetal and postnatal development. One study has
reported that MPR during pregnancy results in the suppression of LXRα expression in the
fetal liver as a result of methylation of the upstream region of the LXRα promoter, but
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effects in postnatal life were not investigated128. As such, the influences of epigenetic
mechanisms on LXR target genes on giving rise to the etiology of the metabolic
syndrome also deserve consideration. Recently, our laboratory has demonstrated that
maternal hypoxia during pregnancy leads to enhanced histone H3 methylation [lysine 9]
surrounding the LXRE region (-258 to -169) of the rat G6Pase promoter by 12 months of
age75, but the effects of under nutrition during perinatal life on long-term LXR activity at
promoter of its target genes remain elusive.
Aside from post-translational histone modifications which may govern the long-term
expression of genes, microRNAs (miRNAs) may also play a key role in the fetal
programming of cholesterol and glucose homeostasis. miRNAs are short, noncoding
RNA molecules of 20-25 nucleotides in length that regulate gene expression via
messenger RNA (mRNA) degradation and/or translational repression163,

164

. By

regulating the expression of target genes, miRNAs have been demonstrated to alter a
variety of physiological processes including cell cycle regulation, differentiation,
metabolism, and aging164. miRNAs silence gene expression by binding to the 3’Untranslated Region (3’-UTR) with partial sequence homology to induce cleavage or
repression of productive translation165. Given their ability to bind 3’-UTR with partial
sequence homology, a single miRNA may have multiple targets in the genome165.
Conversely, given the nature of miRNA targeting, a single mRNA transcript can
theoretically be targeted by several miRNAs165. While miRNAs likely play an important
role in the etiology of adult diseases and cancer, their role in fetal development and
programming remain elusive. Recent microarray studies employing primers for a variety
of miRNAs have demonstrated that maternal nutrient restriction can permanently alter the
expression of miRNAs in the aortas of newborn and aging rat offspring163. Moreover,
circulating hypoxia regulated miRNAs have been demonstrated to be increased in
pregnant women with fetal growth restriction166. The role and identification of miRNAs
altering the expression of genes involved in the fetal programming of cholesterol and
glucose homeostasis remain to be identified, but are the subject of great interest.
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Figure 1.3: Example of how posttranslational modifications to Histone H3 (Lysine 9)
Leading to Chromatin Remodeling. A variety of histone demethylases can remove the
methyl group and histone acetyl transferases (HATs) can add an acetyl group to the same
histone H3 subunit at the Lysine 9 residue leading to an active chromatin environment.
Conversely, a variety of histone deacetylases (HDACs) can remove the acetyl group and
histone methyl transferases (HMTs) can add back the methyl group leading to an inactive
chromatin environment.
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1.7.3

Role of Sex Hormones in the Early Programming of
Metabolic Syndrome

Sex steroid hormones remain an important mediator in long-term regulation of
cholesterol and glucose in adults. It is well established that the onset and severity of
numerous adult diseases differ between men and women. For example, men have higher
24-hour mean blood pressure, by approximately 6 to 10 mm Hg, compared to age
matched premenopausal women, but this trend reverses after women reach menopause167.
In females, it is hypothesized that differences in sex hormones modulate regulatory
systems leading to decreased hypertension and vascular dysfunction167. Given the
widespread origins of the metabolic syndrome, it is difficult to assess whether gender
and, more specifically, sex hormones influence cholesterol catabolism and glucose
homeostasis. Recent studies in animal models have suggested that perturbations to the
maternal environment during pregnancy can lead to sex-specific, long-term consequences
in postnatal life. For example, male offspring of rat dams exposed to 30% global nutrient
restriction

during pregnancy develop

hypertension

earlier than

their female

counterparts62, whereas severe protein restriction (5% protein diet) during pregnancy
results in programmed hypertension in both sexes168. Moreover, an MPR diet during
gestation and lactation results in pancreatic  cell dysfunction and visceral obesity
exclusively in the adult male offspring at postnatal day 13088, 93. The sex specificity exists
even at the epigenetic level in IUGR offspring. For example, uteroplacental insufficiency
induced IUGR rats at postnatal day 21 have a global increase in the females and decrease
in the males with respect to acetylation of Histone H3 (Lysine 9, 14) in the hippocampus
and white matter169. In addition, studies have now demonstrated that sex steroid
hormones can influence epigenetic mechanisms, including post-translational histone
modifications170. Therefore, gender specific differences in the fetal programming of
cholesterol and glucose homeostasis may be due in part to alterations in their “histone
code”.
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1.7.4

‘Impaired Genesis Model’ in the Early Programming of
Metabolic Syndrome

Another important mechanism whereby which early programming of adult diseases can
occur is via the “impaired genesis model”. After a specific period of development in
organs such as the brain, kidney and heart, there is a minimal level of replication and
differentiation potential of the cells from these organs171-175. This model suggests that any
insults during these critical periods permanently alter the function of these organs by
impacting the amount and quality of the long-lasting cells in these organs. For example,
the heart of a newborn contains all the cardiomyocyte cells it requires for the rest of
postnatal life. At term, 90% of these cardiomyocytes are binucleated and are terminally
differentiated. As the heart displays limited plasticity after birth176, any foreseeable insult
during its development can cause permanent changes to its overall growth and function,
which may later manifest into heart dysfunction in adult life. Placental insufficiency
induced IUGR in sheep has been demonstrated to lead to a permanent increase in
proportion of mononucleated cardiomyocytes177. Similarly, several cases exist where
IUGR display alterations in terminal composition and quantity of cells from other organs.
For example, placental insufficiency during the second half of the pregnancy lead to
IUGR guinea pigs, which have a decrease in the number of neurons in the hippocampus
and cerebellum178, a phenotype which could have a long-lasting impact on normal
functioning of the hypothalamus-pituitary axis. Studies with both human and animal
models have provided additional evidence supporting the impaired genesis model by
demonstrating with use of different techniques that IUGR can lead to a lower number of
nephrons, permanently programming kidney function171. External stresses leading to
IUGR can also impact pancreatic and muscle function by way of permanently reducing
pancreatic  cell mass179 and increasing the proportion of type II b muscle fibers which
are known to contain a lower number of mitochondria180. The precise timing of the
nutritional insult is also a critical factor in defining the overall impact of the impaired
genesis model. This is primarily because the timing of the insult would have differing
effects on the development of different organs and hence on disease risks. Moreover, the
impact of an insult during the different windows of organ susceptibility can also differ
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between species174. Therefore, important consideration should be given when
extrapolating findings from one species to another.

1.7.5

Endoplasmic Reticulum Stress in Underlying the Early
Programming of Metabolic Syndrome

The endoplasmic reticulum helps maintain cellular function and survival, as it is essential
for the synthesis, maturation and export of cellular proteins. A variety of insults such as
hypoxia, nutrient deprivation, ischemia, viral or bacterial infection can result in excessive
accumulation of misfolded or unfolded proteins in the ER lumen181. The accumulation of
these proteins triggers the activation of the ER stress pathway, which is also referred to as
the unfolded protein response (UPR)181. UPR aims to alleviate ER stress by decreasing
global protein translation in order to reduce the load of the ER in processing these new
proteins. A reduction in global protein translation is accomplished by an increase in
phosphorylation of eukaryotic Initiation Factor (eIF)-2 at Serine (Ser) 51 residue, which
leads to a rapid reduction in the initiation of mRNA translation182. There is also an
increase in ER chaperone protein levels (i.e. glucose regulated protein Grp78 and Grp94)
to improve ER’s protein folding capacity183,

184

. Furthermore, ER stress induces the

splicing of a highly conserved unconventional 26 bp intron of the X-box binding protein
1 (Xbp-1) mRNA, which encodes for a potent transcription factor involved with
transcriptional upregulation of genes involved in coping with the ER stress183,

184

.

Collectively, an increase in phosphorylation of eIF2 (Ser51), Grp94 and Grp78 protein
levels, and splice variant XBP-1 mRNA level are considered hallmark indicators of
elevated ER stress. Given the critical role of endoplasmic reticulum in overall cellular
functions and survival, any stress to the ER would therefore aggravate the symptoms
associated with the metabolic syndrome.
Over the last decade researchers have established a critical role of ER stress in giving rise
to the risk factors, which characterize the metabolic syndrome in adults185,

186

.

Predominantly, research has focused on identifying the various components in the ER
stress pathophysiology that are linked to molecular mechanisms associated with insulin
resistance and high cholesterol levels187-193. An increase in insulin sensitivity associated
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with weight loss demonstrated a substantial reduction in markers of UPR activation194.
P85α gene, a positive marker of insulin resistance, was demonstrated to bind to and cause
the nuclear translocation of spliced XBP-1 in an ER stress dependent manner195.
Furthermore, Grp78 has been demonstrated to prevent an increase in phosphorylation of
Akt1 at Ser 473 residue, a critical downstream event in the insulin signalling pathway196.
With respect to ER stress association with cholesterol dysregulation, translation
attenuation in ER-stressed cells decreases Insig-1 levels193. As a result, SREBP cleavage
activating protein is released causing the translocation of SREBPs to the Golgi followed
by proteolysis to generate the active SREBP transcription factors. These transcription
factors are involved with activating target genes linked to lipid biosynthesis.
Interestingly, insults such as hypoxia, nutrient deprivation, ischemia, viral or bacterial
infection that result in ER stress due to an accumulation of misfolded proteins, have also
been implicated in placental insufficiency induced intrauterine growth restriction (PIIUGR)182. An elegant study by Yung et al. in 2008 clearly demonstrated a critical role of
ER stress in placental dysfunction in human IUGR197. As placental dysfunction primarily
results in decreased nutrient and oxygen transport to the fetus5,

184-187

, one would

anticipate ER stress to have an adverse effect on the development of IUGR fetal tissues.
However, few studies have been conducted to investigate the evidence of UPR response
in IUGR fetal tissues198. Moreover, the role of ER stress in linking IUGR offspring to
increased risk of developing the metabolic syndrome in adulthood remains poorly
understood. A schematic summary of the major molecular mechanisms underlying the
early life programming of the metabolic syndrome has been provided in Figure 1.4. This
schematic allows for an appreciation of the interdependence which may exist between
these mechanisms, a topic of future investigations.
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Figure 1.4: Mechanisms underlying the early programming of metabolic syndrome. A
variety of insults during pregnancy and weaning including hypoxia, dietary deficiencies,
excess corticosteroids, infection and inflammation can impact important mechanisms
which have been known to contribute to the pathophysiologies related to the metabolic
syndrome. These mechanisms included epigenetic modifications, organelle stress,
endocrine homeostasis and impaired organogenesis. Elucidating some of the
interdependencies which may exist between these mechanisms, remain a topic of future
investigations.
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1.8

The Impact on Drug Metabolism by the Early Programming of
Metabolic Syndrome

Several clinical studies have demonstrated a strong inverse association between birth
weight and metabolic risk factors associated with CVD46-49,

54, 199, 200

. Animal studies

provide further support for this association72, 90, 93, 104, 106, 201. Therefore, low birth weight
offspring would be more likely to be under medication (e.g. statins for
hypercholesterolemia) for the management of symptoms associated with the metabolic
syndrome. Moreover, use of these drugs would be anticipated to occur at an earlier time
in their life. This is particularly relevant in cases where low birth weight offspring
undergo accelerated growth in neonatal life and display these symptoms by adolescent
age35, 36, 38-40, 202. Yet, there is a lack of epidemiological evidence in humans to support the
notion that there is indeed a higher usage of prescribed drugs in adult individuals that are
born low birth weight.
Many clinical factors including age, sex, ethnicity, body mass index, diet (grapefruit and
other fruit juices), drug interactions, lifestyle and genetics can all impact the
pharmacokinetics of a drug in an individual203-208. Surprisingly, little is known about
whether low birth weight represents another significant clinical factor that can also alter
the pharmacokinetics of a drug in adult life. This point deserves consideration because
low birth weight offspring which experience conditions of limited supply of oxygen and
nutrients during gestation, display a hallmark adaptive response where the brain is spared
at the expense of peripheral organs, including the liver. The sparing occurs as a
consequence of redistribution of blood flow from the peripheral organs (i.e. liver) in an
attempt to maintain appropriate oxygen and nutrient supply to the brain209. As a
consequence, liver function is impaired in low birth weight infants210. Furthermore,
animal studies of IUGR have demonstrated long-term alterations in liver function89-92.
Since, the majority of prescribed drugs (~75%) are metabolized in the liver 211, it is likely
that low birth weight offspring with impaired liver function would alter the
pharmacokinetics of drugs in adult life.
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The cytochrome P450 (CYP) family of enzymes are responsible for metabolizing 75% of
the drugs which are eliminated by the liver211. Reduced intravenous midazolam clearance
in preterm infants provides indirect evidence suggesting alteration of hepatic CYP
enzyme activity in low birth weight infants that are 2 to 15 days old212. To date,
intravenous clearance of midazolam is considered the best probe to estimate hepatic
CYP3A4 activity213,

214

, an enzyme responsible for approximately 50% of all drugs

metabolized by CYP family of enzymes211. However, there is little known about the
impact of IUGR in humans on the long-term activity of these drug metabolizing CYP
enzymes. Recently an animal study by Tajima et. al. in 2012 suggested that impaired
development can have a long-term impact on drug metabolizing enzymes in the liver 215.
The study clearly demonstrated that when administering a high fat diet to pregnant mice
there was a decrease in expression and activity of Cyp3a enzyme in the six weeks old
offspring

215

. This coincided with the reduced clearance of trizolam, a substrate of

Cyp3a215. Drug metabolizing enzymes, including Cyp3a and drug transporters, which are
critical for the uptake and efflux of drugs, are known to be regulated by Pregnane X
Receptor (PXR) and Constitutive Androstane Receptor (CAR). These two orphan nuclear
receptors heterodimerize with the Retinoid X receptor (RXR), and subsequently bind to
xenobiotic response elements at the promoter of drug metabolizing enzymes and
transporter genes216. In addition to providing protection from xenobiotic toxicity, recent
evidence demonstrates a physiologically important role of PXR and CAR in lipid and
glucose metabolism217. Therefore, the hypercholesterolemia and impaired glucose
tolerance observed in adult IUGR offspring may likely impact PXR and CAR’s ability to
prevent toxicity from drugs in adult life. Conversely, CAR activation has been
demonstrated to improve insulin sensitivity via glucose and lipid metabolic pathways218.
However, PXR activation results in an increase in lipogenesis despite its ability to
decrease gluconeogenesis217,

219-221

. Not surprisingly, ligand activation of CAR during

pregnancy has been demonstrated to prevent insulin resistance in offspring from high fat
diet induced obese pregnant mice222. However, the effect of this on drug metabolizing
enzymes in the liver was not examined. Interestingly, transient activation of CAR during
neonatal life has been demonstrated to generate a stable epigenetic memory via promoter
specific posttranslational histone modifications, which facilitate a long-term increase in
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some of the Cyp drug metabolizing enzymes223. Despite the recent evidence that early
development impacts hepatic drug metabolizing enzymes long-term, there is still little
known with respect to drug metabolism in adult life of IUGR offspring.

1.9

Summary

Numerous clinical and animal studies have provided evidence for an association between
IUGR and an increased risk of developing cardiovascular disease. It is well established
that impaired cholesterol and glucose homeostasis can significantly increase the risk of
developing cardiovascular disease. Yet the mechanisms underlying the long-term
impairment of cholesterol and glucose homeostasis in IUGR offspring are only beginning
to be elucidated. Most animal models aim to investigate this by inducing IUGR by way of
creating a hypoxic or a nutritionally deprived environment during gestation. The
mechanisms implicated in the cholesterol and glucose homeostasis impairment in IUGR
may include permanent alterations in organ development, hormone regulation, cellular
stresses (i.e. endoplasmic reticulum stress), and/or the global or promoter specific
epigenetic environment. Lastly, considering that IUGR offspring would have a higher
likelihood to be under medications (e.g. statins for hypercholesterolemia), investigating
whether alterations in these mechanisms influence their ability to metabolize drugs in
adult life remains to be determined.
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2

HYPOTHESIS AND SPECFIC AIMS

2.1

Focus of the Thesis

The incidence of metabolic syndrome in Canada is reaching epidemic proportions, with
one in three Canadian family-practice patients between 40 and 60 years of age falling
under this criterion1. Adults with the metabolic syndrome have a ~20-fold risk for
developing cardiovascular disease(CVD)1, a leading cause of premature death world
wide. Most notably, impaired regulation of cholesterol and glucose can lead to a
significant increased risk of developing CVD2,

3

. Several clinical studies have

demonstrated that intrauterine growth restriction (IUGR) offspring, faced with a
nutritional mismatch postpartum, have an increased risk of developing an atherogenic
lipid profile and insulin resistance4-10. Maternal protein restriction (MPR) rat model has
been extensively studied to investigate the adverse effects of a nutritional mismatch in
postnatal life of IUGR offspring. The function of the liver, an important metabolic organ,
has been previously reported to be impaired in the MPR derived offspring11-14. However
the underlying mechanisms, which predispose these offspring to cholesterol
dysregulation and insulin resistance, remain elusive. The overall hypothesis of this thesis
is that long-term alterations in the liver of IUGR offspring may mediate cholesterol
dysregulation in adult life. The focus of the thesis is to identify alterations to key
molecular mechanisms in the liver of MPR derived offspring that may lead to cholesterol
dysregulation in adulthood. The thesis will also evaluate the ‘thrifty phenotype’
hypothesis with respect to whether these alterations become more harmful in conditions
where the MPR derived IUGR offspring are faced with a nutritional mismatch in
postnatal life. Moreover, the impact of this on the long-term ability to metabolize drugs in
the liver will also be determined.
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2.2

Specific Aim 1

To determine whether maternal protein restriction elevated cholesterol in adult rat
offspring via repressive changes in histone modifications at the Cholesterol 7Hydroxylase promoter.
Adverse events in utero, such as intrauterine growth restriction (IUGR), can permanently
alter epigenetic mechanisms leading to the metabolic syndrome, which encompasses a
variety of symptoms including augmented cholesterol. The major site for cholesterol
homeostasis occurs via the actions of hepatic cholesterol 7-hydroxylase (Cyp7a1),
which catabolizes cholesterol to bile acids. Post-translational histone modifications have
been previously demonstrated to regulate Cyp7a1 transcription in adult mice15-17. In
Chapter 3, we sought to determine whether posttranslational histone modifications
influence the long-term expression of Cyp7a1 in IUGR.
Using a maternal protein restriction rat model we hypothesized that IUGR offspring may
lead to elevated cholesterol in adult offspring via repressive changes in histone
modification at the Cyp7a1 promoter. We describe in Chapter 3 that a low protein diet
during pregnancy and lactation led to IUGR offspring with decreased liver to body
weight ratios, followed by increased circulating and hepatic cholesterol levels in both
sexes at day 21 and exclusively in the male offspring at day 130. The augmented
cholesterol was associated with decreases in the expression of Cyp7a1. Chromatin
immunoprecipitation (ChIP) revealed that this was concomitant with diminished
acetylation and enhanced methylation of histone H3 [K9,14], markers of chromatin
silencing, surrounding the promoter region of Cyp7a1. These epigenetic modifications
originate in part due to dietary-induced decreases in fetal hepatic Jmjd2a expression, a
histone H3 [K9] demethylase. Collectively, these findings suggest that the augmented
cholesterol observed in low protein diet derived offspring is due to permanent repressive
posttranslational histone modifications at the promoter of Cyp7a1. Moreover, this was the
first study to demonstrate that maternal undernutrition leads to long-term cholesterol
dysregulation in the offspring via epigenetic mechanisms.
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2.3

Specific Aim 2

To determine whether nutritional mismatch in postnatal life of low birth weight
offspring leads to elevated hepatic endoplasmic reticulum stress in adulthood.
Several clinical studies have demonstrated that low birth weight offspring, as a result of
an adverse in utero environment, have an increased risk of developing the metabolic
syndrome. Moreover, this risk is further exasperated when the low birth weight offspring
is faced with a “nutritional mismatch” in the predictive postnatal environment. In rodent
models, maternal protein restriction derived IUGR offspring when faced with a
nutritional mismatch to normal protein in postnatal life have been previously
demonstrated

to

result

in

impaired

fetal

hypercholesterolemia (Chapter 3) in adulthood

18-20

growth,

glucose

intolerance

and

. Interestingly, there is strong evidence

linking endoplasmic reticulum (ER) stress to both increased cholesterol and insulin
resistance in adults21-29. In Chapter 4, we sought to determine whether ER stress plays a
role in predisposing low birth weight offspring to greater risk of metabolic syndrome.
Therefore, we hypothesized that MPR derived offspring faced with a nutritional
mismatch are at a higher risk of developing metabolic syndrome in adult life due to
presence of elevated hepatic ER stress. To address this hypothesis, pregnant Wistar rats
were fed a control 20% protein diet (C) or a low 8% protein diet during pregnancy and
postnatal life (LP1), during pregnancy and lactation (LP2), or exclusively during
pregnancy (LP3). We describe in Chapter 4 that the LP2 and LP3 offspring which
received a “nutritional mismatch” postpartum, displayed an elevation of established ER
stress markers in the liver, including an increase in X box binding protein 1 mRNA
splicing levels and elevated ER chaperones (Glucose regulated protein 78 and 94) at
postnatal day 130. This was concomitant with attenuated protein synthesis, as indicated
by increased phosphorylation of eukaryotic initiation factor 2 at Ser 51 residue.
However, those offspring that were maintained on low protein diet postpartum (LP1) did
not display elevated ER stress markers. These findings highlight a novel role of ER stress
in predisposing low birth weight offspring, faced with a postnatal “nutritional mismatch”,
to increased risk of developing the metabolic syndrome.
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2.4

Specific Aim 3

To determine whether nutritional mismatch in postnatal life of low birth weight
offspring leads to altered hepatic drug metabolism in adulthood.
Strong clinical evidence exists to support an association between low birth weight and
increased risk of developing the metabolic syndrome. In rodent models, we have
previously demonstrated that maternal protein restriction (MPR) results in impaired fetal
growth and hypercholesterolemia in adulthood (Chapter 3)18. This was attributed to the
long-term repression of hepatic cholesterol 7α-hydroxylase (Cyp7a1), a rate-limiting
enzyme that catabolizes cholesterol to bile acids.

Interestingly, decreased Cyp7a1

expression is associated with Endoplasmic Reticulum (ER) stress in a rat model of
Hypothyroidism30. Moreover, we have recently demonstrated ER stress markers to be
elevated in the livers of adult MPR offspring (Chapter 4). As cytochrome p450 dependent
(Cyp) enzymes reside in the ER of the liver and are the primary enzymes involved with
Phase 1 of drug metabolism, in Chapter 5 we investigated whether their ability to
metabolize substrates is altered in adult life of MPR derived low birth weight offspring.
Therefore, we hypothesized that MPR offspring may have an impaired ability to
metabolize drugs in adulthood. To address this hypothesis, pregnant Wistar rats were
either fed a control 20% protein diet (Control) or a low 8% protein diet throughout life
(LP1) or exclusively during pregnancy and lactation (LP2). We describe in Chapter 5 that
the Cyp3a, Cyp2b and Cyp2c enzymatic activity (Vmax/Km) increased at postnatal day
130, as evaluated by testosterone enzyme kinetics in liver microsomes via ultra
performance liquid chromatography. The increase in activity was associated with an
increase in mRNA levels of Cyp3a1, Cyp2c11, Cyp2b1 as determined through Q-RTPCR. This correlated well with an increase in expression of constitutive androstane
receptor, which is known to regulate transcription of these Cyp enzymes. Collectively,
these findings suggest that a low birth weight offspring may require greater amount of
drugs which are metabolized by Cyp3a, Cyp2b and Cyp2c enzymes in order to exert their
therapeutic effect. This is an extremely relevant finding as it is applicable to those
individuals who are more likely to be prescribed medication (e.g. statins for
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hypercholesterolemia) for the management of the symptoms associated with this
syndrome.
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3.1

Introduction

High circulating cholesterol, in addition to hypertension, central obesity, and insulin
resistance characterize the metabolic syndrome, and remains an important cardiovascular
risk factor in adults1, 2. The major site for the regulation of cholesterol homeostasis occurs
in the liver, mainly through the conversion of cholesterol to bile acids, via the rate
limiting enzyme cholesterol 7α-hydroxylase (Cyp7a1)3. The expression of Cyp7a1 is
under the regulation of the orphan nuclear receptor, the Liver X Receptor (LXR)4. Male
and female mice deficient in Cyp7a1 have elevated circulating cholesterol and decreased
LDL receptors, collectively leading to a ‘proatherogenic’ phenotype5. While current
therapies using the statin class of lipid-lowering drugs have been successful in treating
patients with high cholesetrol6, some patients experience adverse side effects such as
rhabdomyolysis7. Thus, additional novel strategies are warranted to prevent the onset of
hypercholesterolemia and reduce the long-term use of these drugs.

Clinical studies in humans have demonstrated that adverse events in utero that result in
placental insufficiency-induced intrauterine growth restriction (PI-IUGR, representing
8% of newborns), can also alter physiological processes leading to the metabolic
syndrome8, 9. Moreover, 50% of metabolic syndrome-related diseases can be linked to
adverse events in utero10-12. With respect to cholesterol, David Barker and colleagues
have demonstrated that impaired fetal growth is linked to elevated LDL cholesterol and
hypertension in adult humans13, 14. Moreover, the association between birth weight and
cholesterol was more apparent in males and independent of social class, current body
weight, cigarette smoking, and alcohol consumption13. Given that hypercholesterolemia
in mothers is associated with increased incidence of aortic fatty-streaks in fetal and
adolescent life15, it is conceivable that postnatal cholesterol concentrations may be altered
by the perinatal environment, though the underlying molecular mechanisms are unknown.

Various animal models have broadened our understanding of how early nutrition in
pregnancy may influence liver development16-19. The majority of studies have
demonstrated that maternal nutrient or protein restriction leads to decreased liver
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growth16-19. Other studies have demonstrated that a low protein diet during pregnancy
leads to asymmetrical IUGR20, associated with alterations in hepatic glucose output,
decreased glucagon receptor and glucokinase expression, along with increases in insulin
degradation and hepatic lobular volume16, 17. However, very little is known about how
maternal nutrition may alter cholesterol homeostasis in postnatal life. In one study,
maternal dietary iron restriction led to a 21% decrease in fetal growth and an increase in
fetal liver cholesterol21. This was further associated with decreased expression of
Cyp7a121. More recently, a low protein diet throughout pregnancy in mice was
demonstrated to lead to reduced LXRα expression at embryonic day 19.5 22, however the
long-term effects of this in utero nutritional insult on cholesterol homeostasis in postnatal
life remain elusive.

Although transcriptional changes may mediate the expression of target genes involved in
fetal programming, there is limited knowledge on the links between epigenetic
mechanisms in utero and the long-term expression of hepatic target genes

18, 19, 23, 24

.

Previous studies have demonstrated that diminished acetylation and/or an increased
methylation of histone H3 [K9,14] has been associated with chromatin silencing and
decreased RNA Polymerase II binding25,

26

. Elegant studies by Park et al. have

demonstrated that uterine-ligation induced IUGR rat offspring developed type 2 diabetes
as a result of epigenetic silencing of pancreatic and duodenal homeobox 1 (Pdx1), a
critical transcription factor regulating β cell differentiation27. This included both
deacetylation and hypermethylation of histone H3[K9]27. Recently it was demonstrated
that in a model of a low protein diet during pregnancy, LXRα expression was suppressed
in the fetal liver as a result of DNA hypermethylation at the LXRα promoter22, however
the long-term effects of this diet on LXR-target genes (e.g. Cyp7a1) in postnatal life were
not examined. In addition, the effects of a low protein diet on posttranslational histone
modifications during liver development have never been explored.

In the present study, we tested the hypothesis that a low protein diet in pregnancy may
impair cholesterol homeostasis long-term via repressive changes to histone modifications
throughout development in a promoter-specific manner. We observed whether the timing
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of the low protein diet throughout pregnancy and lactation led to increases in circulating
cholesterol in both early (3 weeks) and late (18 weeks) postnatal life. To accomplish this,
four dietary regimes (Control, C; Low Protein, LP1-LP3) were employed to assess the
effects of a low protein diet throughout life (LP1), until the end of lactation (LP2), and
exclusively during gestation (LP3). By examining all three low protein dietary regimes, it
is possible to assess the impact of the duration of the low protein diet and the timing of
protein restoration on liver development and circulating cholesterol. Given that Cyp7a1
plays a major role in regulating cholesterol catabolism in the liver, we also demonstrated
if changes in circulating cholesterol were linked to alterations in Cyp7a1 expression.
Finally, we investigated whether any changes to Cyp7a1 expression in fetal and postnatal
life were due to differences in the acetylation and trimethylation of histone H3 [K9]
surrounding the Cyp7a1 promoter.

3.2
3.2.1

Materials and Methods
Animals and Dietary Regimes

All procedures were performed in accordance with the guidelines set by the Canadian
Council of Animal Care and upon approval of the Animal Care Committee of the
University of Western Ontario. Female and male Wistar rats at breeding age (250 g) were
purchased from Charles River (La Salle, St-Constant, Quebec, Canada). These rats were
housed in individual cages and maintained at room temperature on a 12:12 hour lightdark cycle. For three weeks, these rats were left to acclimatize to the animal care facility
and their reproductive cycles were followed. At the onset of pro-estrous, these rats were
mated. Impregnation was confirmed by the presence of sperm in the vaginal smear the
next morning.
At the onset of proestrus, these rats were mated. Impregnation was confirmed by the
presence of sperm in the vaginal smear the next morning. Upon confirmation of
impregnation (gestation day 1), the rats were fed either a control diet containing 20%
protein (Bio-Serv, Frenchtown, NJ, USA, Product# F4576 – Rodent Diet, AIN-93G,
Blue, ½” pellets) or a LP diet containing 8% protein (Bio-Serv, Frenchtown, NJ, USA,
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Product#F4575 – Rodent Diet, AIN-93G, ½” pellets). The LP diet contained similar fat
content and was made isocaloric (3.61 kcal/gram for control and 3.66 kcal/gram for LP
diet) by the addition of carbohydrates (Bio-Serv, Frenchtown, NJ, USA).
At birth, the litter size was reduced to 8 animals (4 females and 4 males), with weights
closest to the litter mean. This ensured a standard litter size for all mothers. Four different
dietary regimes were administered to these offspring (Table 3.2). Offspring derived from
a maternal low protein diet were either administered the low protein diet throughout
postnatal life (LP1), until the end of lactation (LP2) or until birth (LP3). Otherwise, they
were given a control diet.
Food and water was provided ad libitum and food intake was recorded during pregnancy
and in the offspring. At embryonic day 19 (e19), a subset of pregnant rats were sacrificed,
and the weights of the fetus, placenta and liver were measured, and the fetal liver was
excised and frozen. Another subset of rats was allowed to deliver spontaneously. The
growth curves and food intake of these offspring were monitored by measuring their
body weight and food consumption every third day. At both postnatal day 21 (d21), the
selected time for weaning, and at postnatal day 130 (d130), the pups were also sacrificed
for blood and medial lobe liver tissue analysis.

3.2.2

Plasma Lipid Measurements

Measurements of total cholesterol and triglycerides from plasma of all blood samples was
automatically detected using the COBAS® analyzer (Roche, Mississauga, Ontario,
Canada) at St. Joseph’s Health Care (London, Ontario, Canada). For the measurement of
circulating cholesterol, cholesterol esters were cleaved by cholesterol esterase and
subsequently converted to cholest-4-en-3-one and hydrogen peroxide by cholesterol
oxidase. A colorimetric assay resulting from breakdown of hydrogen peroxide via the
Trinder reaction allowed for the quantification of cholesterol levels.
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3.2.3

Hepatic Cholesterol Measurements

In order to determine the total amount of cholesterol present in hepatic tissue, a (1:1)
chloroform:methanol extraction was performed in order to extract and separate total
cholesterol and phospholipids from aqueous matter. After samples were dried, the total
amount of cholesterol was determined by the Amplex®Red Cholesterol Assay Kit
(Invitrogen, Carlsbad, CA, USA) which produces resorufin as a cholesterol by-product.
This was measured using a fluorescence spectrometer at 590 nm.

3.2.4

Real Time PCR Analysis

Total RNA from Wistar rat medial lobe liver tissue was extracted at e19, d21 and d130
by the one-step method of Chomczynski and Sacchi28 (TRIzol, Invitrogen, Carlsbad, CA,
USA). RNA was treated with deoxyribonuclease to remove any contaminating DNA. 4
µg of the total RNA was reverse transcribed to cDNA using random primers and
Superscript II RNase H-reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Primer
sets directed against rat Jmjd2a, Jmjd2c, Jmjd2d, β-actin, and Hprt (ribosomal RNA)
were generated via Primer Express software (PE Applied Biosystems, Boston, MA, USA)
based on published sequences (Table 3.1). The relative abundance of each transcript was
determined by real-time quantitative PCR as previously published29. For the quantitative
analysis of mRNA expression, the Bio-Rad CFX384 Real Time System was employed
using the DNA binding dye IQTM SYBER green supermix (Bio-Rad, Mississauga,
Ontario, Canada). The cycling conditions were 50 C for 2 min, 95 C for 10 min, followed
by 45 cycles of 95 C for 15 sec, and 60 C for 1 min. The cycle threshold was set at a level
where the exponential increase in PCR amplification was approximately parallel between
all samples. All primer sets produced amplicons of the expected size and sequence. We
calculated the relative fold changes using the comparative cycle times (Ct) method with
ribosomal RNA (Hprt) or β-actin as the reference guide. Over a wide range of known
cDNA concentrations, all primer sets were demonstrated to have good linear correlation
(slope=-3.4) and equal priming efficiency for the different dilutions compared with their
Ct values (data not shown). Given that all primer sets had equal priming efficiency, the
∆Ct values (primer internal control) for each primer set were calibrated to the

63

experimental samples with the lowest transcript abundance (highest Ct value), and the
relative abundance of each primer set compared with calibrator was determined by the
formula, 2∆∆Ct, in which ∆∆Ct is the calibrated Ct value.

3.2.5

Chromatin Immunoprecipitation (ChIP)

ChIP was performed on snap frozen medial lobe liver tissue excised at e19, d21 and d130
from male and female offspring derived from the Control or LP2 dietary regime. ChIP
was performed using a modification30 of previously published methods31. Briefly, a small
piece of snap frozen liver was homogenized and incubated with 1% formaldehyde for 10
min at room temperature to cross-link proteins and DNA. Crosslinking was terminated by
the addition of Glycine (0.125M, final concentration). The liver tissue was washed once
with cold PBS and placed in 500 l of SDS lysis buffer (Millipore, Etobicoke, Ontario,
Canada) with protease inhibitor cocktail (Roche, Mississauga, Ontario, Canada). The
lysates were sonicated on ice to produce sheared, soluble chromatin. The lysates were
diluted ten times with the addition of ChIP dilution buffer (Millipore, Etobicoke, Ontario,
Canada) and aliquoted to 400 l amounts. Each of the aliquots was precleared with
protein A/G Plus agarose beads (40 µl, Millipore, Etobicoke, Ontario, Canada) at 4°C for
30 minutes. The samples were microfuged at 12500 rpm to pellet the beads, and the
supernatant containing the sheared chromatin was placed in new tubes. The aliquots were
incubated with 4 µg of antibodies against RNA Polyermase II (cat #05-623B), acetylated
histone H3 (lysine 9,14, cat #05-399), trimethylated histone H3 (lysine 9, cat# 07-442, all
from Millipore, Etobicoke, Ontario, Canada), or Liver X Receptor (LXR, cat# sc13068x, Santa Cruz Biotechnology, Santa Cruz, California) at 4°C overnight. Two
aliquots were reserved as ‘controls’ – one incubated without antibody and the other with
non-immune IgG (Millipore, Etobicoke, Ontario, Canada). Protein A/G Plus agarose
beads (60 l) were added to each tube, the mixtures incubated for 1 h at 4°C and the
immune

complexes

collected

by

centrifugation.

The

beads

containing

the

immunoprecipitated complexes were washed sequentially for 5 min in wash buffer I (20
mM Tris-HCl, pH 8.1, 2 mM EDTA, 0.1% SDS, 1% Triton X-100, 150 mM NaCl), wash
buffer II (same as I, except containing 500 mM NaCl), wash buffer III (10 mM Tris-HCl,
pH 8.1, 1 mM EDTA, 1% NP-40, 1% deoxycholate, 0.25 M LiCl), and in 2  TE buffer.
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The beads were eluted with 250 l elution buffer (1% SDS, 0.1mM NaHCO3 + 20 g
salmon sperm DNA (Sigma-Aldrich, Oakville, Ontario, Canada) at room temperature.
This was repeated once and eluates were combined. Crosslinking of the
immunoprecipitated chromatin complexes and ‘input controls’ (10% of the total soluble
chromatin) was reversed by heating the samples at 65C for 4 h. Proteinase K (15 µg,
(Invitrogen, Carlsbad, CA, USA) was added to each sample in buffer (50 mM Tris-HCl,
pH 8.5, 1% SDS, 10 mM EDTA) and incubated for 1 h at 45C. The DNA was purified
by phenol-chloroform extraction and precipitated in EtOH overnight at 20C. Samples
and ‘input’ controls’ were diluted in 10-100 l TE buffer just prior to PCR. Real-time
PCR was employed using forward (5’-TGCTTTGGTCACTCAAGTTCA-3’) and reverse
(5’-GCAATTCCCCAAATCAAAGA-3’) primers that amplify a -164 bp to +65 bp
region encompassing the TATA box and the Cyp7a1 initiation site32, forward (5’CGTAGCTCAGGCCTCTGCGCCCTT-3’)

and

reverse

(5’-CTGGCACTGCAC-

AAGAAGATGCGGCTG-’) primers that amplify a -123 bp to +53 bp region
encompassing the TATA box and the rat Gapdh initiation site33, and forward (5’GGCCGGGTAATGCTATTTTT-3’) and reverse (5’-CCGAAACAGTGGGTCTGACT3’) primers that amplify a -156 bp to +25 bp region encompassing the rat Cyp7a1 LXRE
site (-128 bp to -81 bp) and the TATA box (PE Applied Biosystems, Boston, MA,
USA)32. Using serial dilutions of rat liver chromosomal DNA, these primers were
employed because this region has equal efficiency in priming to their target sequences.
Primers against distal regions of the Cyp7a1 promoter were employed to ensure this
region has the greatest recruitment of RNA Polymerase II.

3.2.6

Preparation of Tissue Membrane Extracts and Immunoblot
Analysis

Wistar rat liver tissue membrane extracts were prepared using modifications of
previously published methods34. Briefly, a small piece of snap frozen medial lobe liver
tissue was homogenized in a 1.2 ml of buffer A solution (250mM Sucrose, 2mM MgCl2,
20mM Tris-HCl at overall pH 7.5) with protease inhibitor cocktail (Roche, Mississauga,
Ontario, Canada). The homogenate was centrifuged at 2000 g for 10 min at 40C. The
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supernatant was retained and buffer A was added. This was centrifuged at 120,000 g for
45 min at 40C and the pellet was retained as the membrane fraction which was
resuspended in 200 ul of buffer B (80 mM NaCl, 2mM CaCl2, 1% Triton X-100, 50mM
Tris-HCl at overall pH 8) with protease inhibitor cocktail (Roche, Mississauga, Ontario,
Canada). Equal concentrations of membrane proteins normalized by colorimetric BCA
Protein Assay (Pierce Corp., Madison, WI, USA), were fractionated in gradient
polyacrylamide gels (Invitrogen, Carlsbad, CA, USA) and transferred onto PVDF
membrane (Millipore, Etobicoke, Ontario, Canada). Blots were probed using Cyp7a1
rabbit polycolonal antibody (1:500, cat #sc-25536, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), LXR (Liver X Receptor (cat# sc-13068x, Santa Cruz Biotechnology,
Santa Cruz, California) and monoclonal HRP conjugated β-Actin (1:50,000, cat#A3854,
Sigma-Aldrich, Oakville, Ontario, Canada) diluted in 5 % milk-1xTris-buffered salineTween 20 buffer and with horseradish peroxidase conjugated donkey anti-rabbit IgG
(1:10,000, cat#711-035-152, Jackson ImmunoResearch Laboratories, West Grove, PA,
USA) diluted in 5 % milk-1x Tris-buffered saline-Tween 20 buffer as the secondary
antibody. Immunoreactive bands were visualized using an enhanced chemiluminescence
detection system (Thermo Scientific, Waltham, MA, USA).

3.2.7

Statistics

All results were expressed as the mean of arbitrary values  the standard error of the
mean (SEM). The significance of differences (p<0.05) between mean values were
evaluated using the unpaired Student’s t-test for results from qRT-PCR, ChIP and
Immunoblot analysis. Two and one-way analysis of variance (ANOVA) followed by a
Bonferroni’s Multiple Comparison post hoc test, was used to evaluate significance of
differences for results comparing the effect of all the dietary regimes.
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Table 3.1. Real Time PCR primers
Gene

Primer (5’-3’)

Reference No.

Jmjd2a

FWD GCG AGC AGG AGC TGG CAG AG

NM 001107966

REV AAC ACC AGC GGG TGA TGG CG

NM 001107966

FWD GCG AGC TGG TGG AGC TGC GG

BC161813

REV GGG ACC GTA CCC TCT TGG GC

BC161813

FOR TAC ATC CGT CTC CAG TCC AAA A

NM 013134

REV CAG GTT TCT TGT CGG TGC AA

NM 013134

FOR GGG TTC CAT AGG GTT TCT GCT

NM 175762

REV TGG TAT ACT CGC TGC GGT CC

NM 175762

FWD ATG GAG GAG TTT CGG GAG TT

BC158850

REV CAT GGG CTT TTT CTG GAT GT

BC158850

FWD GGG GCA GCC ACG AGC TTT CC

NM 001079712

REV GGG CAT CAG CTC AGT CAG GG

NM 001079712

FWD TTG CTC GAG ATG TCA TGA AGG A

NM 012583

Jmjd2b

Hmg-CoA
Reductase

Ldlr

Jmjd2c

Jmjd2d

Hprt

REV AGC AGG TCA GCA AAG AAC TTA TAG NM 012583
β-actin

FWD ACG AGG CCC AGA GCA AGA

NM 031144

REV TTG GTT ACA ATG CCG TGT TCA

NM 031144
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3.3

Results

3.3.1

A low protein diet during pregnancy and lactation leads to
impaired body weight and liver growth

A low protein diet during pregnancy has been previously demonstrated to decrease birth
weight16-19 and lead to increases in visceral fat, impaired glucose tolerance, and
symptoms of type II diabetes in adulthood35-38 in the rat offspring. Although others have
demonstrated that offspring derived from this low protein dietary regime were not
hypertensive at 4 weeks of age39, low protein females placed on a high carbohydrate diet
after lactation exhibited elevated systolic blood pressure at 1 year of age40. In this study,
a low protein diet resulted in a significant decrease in fetal to placental weight ratio and a
marked decrease in fetal liver to body weight ratio at embryonic day 19 (Table 3.2). In
agreement with previous reports41, 42, a low protein diet did not alter maternal food intake
and there was no observed change in litter size or sex ratio (Figure 3.1A). To further
examine the effect of the timing and duration of the low protein diet on postnatal growth
and liver development, various dietary regimes (LP1, LP2, LP3) were implemented
(Table 3.2). At day 21, there was a significant decrease in both body weight and liver to
body weight ratio in the male and female offspring derived from the LP1/LP2 diet
compared to control (Table 3.2). However, offspring of either sex derived from the LP3
dietary regime displayed no difference in body weight and liver to body weight ratios
when compared to the offspring derived from the control diet. We next observed the
effects of LP1-LP3 on liver and body growth at 130 days of age. We examined this age
based on our previous study which demonstrated sex-specific differences in glucose
homeostasis at this time point42. While the body weights of LP1 or LP2 male and female
offspring regimes remained significantly lower at day 130, their liver to body weight ratio
was restored compared to the control animals (Table 3.2). Furthermore, no change in the
food intake of the offspring was observed in the four dietary regimes (C, LP1-3; data not
shown), suggesting that it was a difference in the protein content of the diet and not
appetite that was a primary factor in inducing any of the observed developmental
changes.
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Table 3.2. The effect of LP dietary regimes LP1, LP2, LP3 on liver growth and body
weight in rat offspring at embryonic day 19 (e19), postnatal day 21 (d21), and postnatal
day 130 (d130)

Dietary regimes and the liver to body weight ratio of offspring. To assess body weight
(g), the fetal to placental weight ratio was determined for offspring killed at e19, and the
body weight was determined for offspring killed at d21 and d130. To assess liver growth,
liver to body weight ratio was determined for all three developmental time points. All
data was expressed as SEM. For e19, dietary effects were determined using Student’s
unpaired t test whereas for d21 and d130, a one-way ANOVA followed by a Bonferroni’s
Multiple Comparison post hoc test was performed. a = Significant difference (P < 0.05)
vs. control (n = 10–14/group). N/A refers to when the LP dietary regimes were the same.

B.
Weight of Food Eaten (g/day/animal)

A.
34
32
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28
26
24
22
20
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Low Protein (8% Protein) Diet
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Gestational
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grams)

69

200

150

100

50

0
Control
Control

Low Protein
Protein

Dietary Regime
Regime

Figure 3.1: Effect of maternal low protein diet on A. Maternal Food Intake and B.
Maternal Weight. Pregnant rats were given either a control diet (20% protein) or a low
protein diet (8% protein) during gestation. Weight of food eaten in g/day/animal and
maternal weight gain from gestation day 1 to gestation day 22 in grams were measured,
respectively. Results were expressed as the mean ± SEM.* = significant difference
(p<0.05). n=4-6/group, where each n represents a different mother.
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3.3.2

A low protein diet during pregnancy and lactation leads to
augmented circulating cholesterol in both sexes in early
development, and exclusively in the male offspring in
adulthood

To determine whether LP1-LP3 led to postnatal changes in cholesterol levels, total
circulating cholesterol was measured in the offspring at day 21 and day 130 . Total
circulating cholesterol levels was observed to be significantly increased in the male and
female offspring derived from the LP1/LP2 dietary regime at day 21 (Figure 3.2A) and
exclusively in the male offspring derived from the LP2 dietary regime at day 130 (Figure
3.2B). In addition, hepatic total cholesterol concentrations were similarly increased in
male LP2 offspring at day 130 (Figure 3.2C). In a small cohort of control animals given a
low protein diet from birth to day 21 (reverse LP3), circulating cholesterol was not
significantly different from the control or LP3 offspring (Figure 3.2A). The increase in
hepatic cholesterol in LP2 males at day 130 was not attributed to alterations in Hmg-CoA
reductase or the LDL receptor (Figure 3.3). Furthermore, when plasma triglycerides were
measured at day 21 and day 130, there was no statistical difference in triglyceride
concentrations between any dietary groups at both ages (data not shown).
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Figure 3.2: The effect of different low protein dietary regimes on A. circulating
cholesterol concentrations (mM) in rat offspring at postnatal d 21 (n=10-14/group), B.
postnatal d 130 (n=10-14/group). C. The effect of LP2 on median lobe liver total
cholesterol at postnatal d 130 (n=5-6/group). Results were expressed as the mean ± SEM.
Dietary effects were determined using a two-way analysis of variance (ANOVA)
followed by a Bonferroni’s Multiple Comparison post hoc test. ** = significant
difference (p<0.01) & * = significant difference (p<0.05) vs male control, ## =
significant difference (p<0.01) vs female control.
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Figure 3.3: The effect of the LP2 dietary regime on hepatic 3-Hydroxy-3-methylglutarylcoenzyme A reductase (Hmg-CoA reductase) and low-density lipoprotein receptor (Ldl
receptor) in A, C male and B, D female rat offspring at postnatal d 130, respectively.
Relative hepatic Hmg-CoA reductase and Ldl receptor protein levels were determined
using Western blot analysis. Total protein was isolated and Hmg-CoA reductase and Ldl
receptor protein was detected on a western blot using the Hmg-CoA reductase and Ldl
receptor primary antibody. The Hmg-CoA reductase and Ldl receptor protein levels were
quantified using densitometry and normalized to that of β-actin protein levels. Results
were expressed as the mean ± SEM.* = significant difference (p<0.05). n=5-6/group,
where each n represents a single offspring derived from a different mother.
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3.3.3

Decreases in Cyp7a1 protein levels coincide with the
respective increases in total circulating cholesterol levels in
offspring derived from the LP2 dietary regime at day 21 and
day 130

To elucidate the underlying mechanisms for the augmented cholesterol in the LP2
offspring, immunoblot analysis was performed to determine the protein levels of hepatic
Cyp7a1, the rate limiting enzyme involved in the conversion of cholesterol to bile acids,
during fetal and postnatal development. At embryonic day 19, a low protein diet led to a
significant decrease in hepatic Cyp7a1 protein levels (Figure 3.4A). At day 21, both the
male and female offspring derived from the LP1/LP2 dietary regime also had
significantly lower Cyp7a1 protein levels (Figure 3.4B,C), which was associated with the
augmented circulating cholesterol observed in both sexes at this age (Figure 3.2A).
Interestingly, when maternal proteins were restored to the low protein offspring during
lactaction (LP3), Cyp7a1 protein levels significantly increased compared to control
(Figure 3.4D). Finally, when the expression of hepatic Cyp7a1 was examined in both
sexes from the LP2 dietary regime at day 130, only the male LP2 offspring exhibited
significant decreases in Cyp7a1 protein levels (Figure 3.4E,F). This gender-specific
decrease in Cyp7a1 coincided with changes in circulating and hepatic cholesterol at this
age (Figure 3.2B,C).
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Figure 3.4. The effect of the LP2 dietary regime on hepatic Cyp7a1 protein levels in rat
offspring at embryonic d 19 (A), male (B), and female (C) rat offspring at postnatal d 21
and male (E) and female (F) rat offspring at postnatal d 130. (D) The effect of LP3
dietary regime on hepatic Cyp7a1 protein levels in male rat offspring at postnatal d 21.
Relative hepatic Cyp7a1 protein levels were determined using Western blot analysis.
Total membrane protein was isolated and Cyp7a1 protein was detected on a Western blot
using the Cyp7a1 primary antibody. The Cyp7a1 protein level was quantified using
densitometry and normalized to that of β-actin protein levels. Results were expressed as
the mean ± SEM. *, Significant difference (P < 0.05); n = 4–7/group, where each n
represents a single offspring derived from a different mother.
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3.3.4

The LP2 induced reduction in hepatic Cyp7a1 protein in the
male offspring is due to a decreased recruitment of RNA
Polymerase II at the Cyp7a1 initiation site throughout fetal
and postnatal development

To

explore

the

effects

of

LP2

on

transcriptional

mechanisms,

chromatin

immunoprecipitation (ChIP) was employed to examine the recruitment of RNA
Polymerase II to the Cyp7a1 initiation site. Quantitative real-time PCR was used to
amplify an approximate 100 bp genomic region surrounding the TATA box and the
initiation site (Figure 3.5A,C,E,G). This region was demonstrated to have maximal
enrichment of RNA Polymerase II compared to distal sites of the Cyp7a1 promoter
(Figure 3.6). At embryonic day 19, it was observed that there was a significant decrease
in the recruitment of RNA Polymerase II to the initiation site of hepatic Cyp7a1 in the
low protein fetuses (Figure 3.5A). Moreover, the decreased binding of RNA Polymerase
II to the Cyp7a1 promoter persisted in the LP2 derived male offspring at both day 21 and
day 130 (Figure 3.5C,E). The decrease in recruitment of RNA polymerase II was specific
to the Cyp7a1 promoter region given no significant alterations in its recruitment was
observed at the promoter of Gapdh, a housekeeping gene (Figure 3.5B,D,F,H). ChIP
performed using non immune IgG displayed negligible level of binding to either the
Cyp7a1 and Gapdh promoter region. The decrease in the recruitment of RNA Polymerase
to the promoter of Cyp7a1 in LP2 offspring corresponded with both the decrease in
Cyp7a1 protein levels (Figure 3.4A,B,D) and augmented cholesterol (Figure 3.2A,B).
Given that there were sex-specific differences in circulating cholesterol and Cyp7a1
expression between males and females at day 130, the recruitment of RNA Polymerase II
to the Cyp7a1 promoter was examined at that age for both sexes. Unlike the males, ChIP
revealed no corresponding differences in RNA Polymerase II binding to the promoter of
Cyp7a1 in the females at this age (Figure 3.5G).
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Figure 3.5. The effect of the LP2 dietary regime on the in vivo RNA polymerase II (RNA
Pol II) binding at the initiation site of hepatic Cyp7a1 (A, C, E, and G) and the initiation
site of Gapdh gene (B, D, F, and H) in rat offspring at embryonic d 19 (e19), male rat
offspring at postnatal d 21, male and female rat offspring at postnatal d 130, respectively.
ChIP was carried out on snap-frozen liver tissues by immuneprecipitation with antibody
specific for RNA polymerase II. Quantification analysis on the immunoprecipitated
solubilized DNA was carried out by real-time PCR via use of primers specific for the
initiation sites on the promoter regions of hepatic Cyp7a1 and Gapdh. The relative level
of immunoprecipitated genomic DNA was normalized to the total genomic DNA. Results
were expressed as the mean ± SEM.*, Significant difference (P < 0.05); n = 4– 6/group,
where each n represents a single offspring derived from a different mother.
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Figure 3.6. In vivo RNA Polymerase II recruitment at three sites upstream of the hepatic
Cyp7a1 promoter by employing ChIP with use of primers encompassing -2000 bp, 500bp and the TATAA box regions of a control male rat offspring at postnatal day 21.
ChIP was carried out on snap frozen liver tissues by immuneprecipitation with antibody
specific for RNA Polymerase II. Quantification analysis on the immunoprecipitated
solubilzed DNA was carried out by real time PCR via use of primers specifically
targeting the -2000 bp, -500 bp and the TATAA box regions on hepatic Cyp7a1. The
relative level of immunoprecipitated genomic DNA was normalized to the total genomic
DNA. Results were expressed as the mean ± SEM.
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3.3.5

Decreased recruitment of RNA Polymerase II in the LP2
dietary regime is associated with chromatin silencing of
Cyp7a1 promoter region via posttranslational histone
modifications

It is well established that decreased acetylation and/or an increased methylation of
histone H3 [K9,14] is associated with chromatin silencing and decreased RNA
Polymerase II binding25,

26

. Therefore, to investigate whether posttranslational histone

modifications influenced chromatin remodeling and RNA polymerase II recruitment to
the Cyp7a1 promoter during LP2, we employed ChIP utilizing antibodies directed against
histone H3 methylation [K9] and/or acetylation [K9,14]. At embryonic day 19, an
increase in the acetylation of histone H3 (Figure 3.7A), but no change in trimethylation
(Figure 3.7B) was observed surrounding the active site of Cyp7a1 promoter. This was
despite the fact that the protein levels of Cyp7a1 were slightly reduced (Figure 3.4A).
However, a significant decrease in the acetylation along with an increase in the
methylation of histone H3 [K9], was observed at the hepatic Cyp7a1 promoter derived
from LP2 male offspring at both day 21 (Figure 3.5C,D) and day 130 (Figure 3.5E,F). At
both ages in LP2 males, these epigenetic changes correspond exactly with the observed
decreased recruitment of RNA Polymerase II in the Cyp7a1 promoter (Figure 3.5C,E),
diminished expression of Cyp7a1 (Figure 3.4B,D), and the observed increases in
circulating and hepatic cholesterol (Figure 3.2A,B,C). In contrast, no alterations the
acetylation [K9,14] or methylation [K9] of histone H3 were observed at the hepatic
promoter of Gapdh at this age (Figure 3.8). Interestingly, in day 130 females, where no
differences in circulating cholesterol or Cyp7a1 expression were observed (Figure 3.2B,
3.4E), there was also no corresponding changes in acetylation (Figure 3.7G) or
methylation (Figure 3.7H) surrounding the active site of Cyp7a1.
Given that the methylation of histone H3 [K9] can be influenced by specific [K9]
demethylases26, we next examined whether changes in their expression facilitated the
increases in the trimethlyation of histone H3 [K9] associated in the LP2 males. We
examined only the steady state mRNA levels of those [K9] demethylases (Jmjd2a,
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Jmjd2b, Jmjd2c, Jmjd2d) that removed trimethyl groups from [K9] of histone H326. Realtime quantitative PCR revealed that significant decreases in the hepatic Jmjd2a mRNA
were observed only at embryonic d19 in LP fetuses (Figure 3.9A). No significant changes
in the hepatic mRNA levels of Jmjd2b and Jmjd2c were observed between diets at this
age, although there was a trend for a decrease in their expression due to the LP diet
(Figure. 3.9B,C). The steady-state mRNA level of all of these [K9] demethylases was the
same at d 21 (Figure 3.9D,E,F) and undetectable at d 130 in the control and LP2 dietary
regimes (data not shown). The hepatic Jmjd2d mRNA was low to undetectable at all ages
examined. This LP diet-induced decrease in the fetal hepatic expression of this [K9]
demethylase may initiate the hypermethylation of histone H3 surrounding the
Cyp7a1promoter observed in LP2 offspring.
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Figure 3.7: The effect of LP2 dietary regime on the in vivo level of acetylated histone H3
[K9,14] (A, C, E, and G) and trimethylated histone H3 [K9] (B, D, F, and H) at the
hepatic Cyp7a1 LXRE site in rat offspring at embryonic d 19 (e19), male rat offspring at
postnatal d 21, male and female rat offspring at postnatal d 130, respectively. ChIP was
carried out on snap-frozen liver tissues by immunoprecipitation with antibodies for
acetylated histone H3 [K9,14] and trimethylated histone H3 [K9]. Quantification analysis
on the immunoprecipitated solubilized DNA was carried out by real-time PCR via use of
primers specific for the LXRE site on the promoter regions of hepatic Cyp7a1. The
relative level of immunoprecipitated genomic DNA was normalized to the total genomic
DNA. Results were expressed as the mean ± SEM.*, Significant difference (P < 0.05); n
= 4–6/group, where each n represents an offspring derived from a different mother. RXR,
Retinoid X receptor.
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Figure 3.8: The effect of LP2 dietary regime on the in vivo level of A. Acetylated
histone H3 [K9,14] and B. Tri-methylated histone H3 [K9] at the hepatic Gapdh initiation
site in male rat offspring at postnatal day 130, respectively. ChIP was carried out on snap
frozen liver tissues by immuneprecipitation with antibodies for acetylated histone H3
[K9,14] and trimethylated histone H3 [K9]. Quantification analysis on the
immunoprecipitated solubilzed DNAwas carried out by real time PCR via use of primers
specific for the initiation site on the promoter regions of hepatic Gapdh. The relative level
of immunoprecipitated genomic DNA was normalized to the total genomic DNA. Results
were expressed as the mean ± SEM.* = significant difference (p<0.05). n=4-6/group,
where each n represents an offspring derived from a different mother.
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3.3.6

Protein restoration during lactation (LP3 dietary regime)
enhances the recruitment of LXR to the promoter of
Cyp7a1 at postnatal day 21

Given the important role of LXR in the transcriptional regulation of Cyp7a1, we next
investigated whether hepatic LXR levels were altered in the low protein offspring by
postnatal day 21, the earliest time point of cholesterol dysregulation and impaired
Cyp7a1 expression. Intriguingly, in both LP2 and LP3 offspring, increases in total
hepatic LXR protein levels (Figure 3.10A,B) were observed. We next employed ChIP
to investigate the in vivo binding of LXR to the promoter of Cyp7a1 containing a well
characterized LXRE site. Despite an increase in total LXR, LP2 offspring did not
exhibit any alterations in the binding of LXR to the promoter of Cyp7a1 at day 21
(Figure 3.10C). However, when the low protein offspring received a 20% protein diet
during lactation (LP3), LXR binding was enhanced (Figure 3.10D). This is in
association with restored Cyp7a1 expression in this dietary cohort (Figure 3.4D).
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Figure 3.9: Quantitative RT-PCR mRNA level analysis of Jmjd2a (A and D), Jmjd2b (B
and E), and Jmjd2c (C and F) in the livers of rat offspring derived at embryonic d 19
(e19) and male rat offspring at postnatal d 21, respectively. RNA was extracted and
reverse transcribed for quantitative RT-PCR. mRNA level expression was assessed via
Q-RT-PCR using primers specific for Jmjd2a, Jmjd2b, Jmjd2c, and Hprt. The relative
levels of each mRNA transcript were normalized to that of the levels of each Hprt mRNA
transcript. Results were expressed as the mean ± SEM. *, Significant difference (P <
0.05); n = 4–9/group at embryonic d 19, where each n represents an offspring derived
from two different mothers and n = 5–6/group at postnatal d 21, where each n represents
an offspring derived from a different mother.
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Figure 3.10: The effect of LP1/LP2 (A and C) and LP3 (B and D) dietary regime on
hepatic LXR_ protein and binding levels to Cyp7a1 LXRE site in rat offspring at
postnatal d 21. Relative hepatic LXRα protein levels were determined using Western blot
analysis. Total protein was isolated and LXRα protein was detected on a Western blot
using the LXRα primary antibody. The LXRα protein level was quantified using
densitometry and normalized to that of β-actin protein levels. Relative hepatic LXR_
binding levels to Cyp7a1 LXRE site were determined using ChIP analysis. ChIP was
carried out on snap-frozen liver tissues by immunoprecipitation with antibody specific for
LXRα. Quantification analysis on the immunoprecipitated solubilized DNA was carried
out by real-time PCR via use of primers specific for the LXRE site on the promoter
regions of hepatic Cyp7a1. The relative level of immunoprecipitated genomic DNA was
normalized to the total genomic DNA. Results were expressed as the mean ± SEM.*,
Significant difference (P < 0.05); n = 4–7/group, where each n represents a single
offspring derived from a different mother. RXR, Retinoid X receptor.
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3.4

Discussion

In this study we present evidence for the first time that a low protein diet during
pregnancy and lactation led to hypercholesterolemia in both sexes at postnatal day 21,
with augmented cholesterol persisting in the male offspring at day 130. This was found to
coincide with transcriptional repression of Cyp7a1, governed in part due to changes in
posttranslational histone modifications surrounding the Cyp7a1 promoter during
postnatal life. Moreover, low protein diet-induced decreases in the steady-state levels of
Jmjd2a mRNA in utero may mediate the increased trimethylation of histone H3 (lysine 9)
associated with this promoter at postnatal day 21 and day 130. These identified epigenetic
and transcriptional mechanisms help in further understanding the link between IUGR and
long-term cholesterol dysregulation. Uncovering these molecular mechanisms is critical
given 50% of metabolic syndrome-related diseases can be linked to adverse events in
utero10-12. In identifying some of the epigenetic mechanisms underlying the in utero
origins of hypercholesterolemia, this study helps identify early life dietary and/or drug
intervention strategies to lower cholesterol and reduce the incidence of the metabolic
syndrome. Such strategies could reduce the long-term use of cholesterol lowering drugs
in adulthood.
As expected from previous studies by others(14-17) and in our laboratory16-19, a low
protein diet resulted in reduced fetal to placental weight, neonatal growth, and liver to
body weight ratio by postnatal day 21. Furthermore, this decrease in body weight
persisted to adulthood (day 130) in offspring derived from a low protein diet during
pregnancy and lactation, with (e.g. LP2) or without (e.g. LP1) a restoration in maternal
protein content after lactation. This compliments previous studies suggesting that a low
protein diet in early development has long-term implications on the overall growth of
rats38. The maternal protein restriction model of IUGR in rats is a relevant model to study
the fetal origins of adult diseases given that amino acids play a critical role in fetal
growth43. Moreover, given placental insufficiency in humans can produce protein
deficiency in the fetus44, this model share features in common with human PI-IUGR. The
impaired body weight is due to the low protein content in the diet given that maternal
food intake was similar in all dietary regimes. Interestingly, the liver to body weight ratio
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of offspring was not significantly different at postnatal day 130 in any dietary regime,
suggesting that the impaired liver growth is ultimately recovered by adulthood, even
though deficiencies in body weight may still be apparent.
As evident from their body weight at day 21, restoration of protein in the maternal diet at
birth (e.g. LP3) resulted in complete catch-up growth in these offspring, with no changes
in the liver to body weight ratio. Moreover, they also exhibited enhanced Cyp7a1 protein
levels, contributing to the prevention of hypercholesterolemia. Given that during this
period there is a high rate of replication, neogenesis, and apoptosis leading to extensive
liver remodeling in the newborn45, it is not surprising that a restoration of protein in the
maternal diet during this developmental window rescued hepatic growth and function.
Other studies have implicated the neonatal period as a period of plasticity in liver
development23,

46

. Stoffers et al. have demonstrated that in IUGR rats derived from

uterine-ligated dams, neonatal administration of Exendin-4 (a GLP-1 analog), prevents
the development of hepatic oxidative stress and insulin resistance23. Further
understanding the molecular mechanisms underlying this plasticity could lead to
improved therapies designed to enhance hepatic growth and function long-term.
A low protein diet during pregnancy and lactation (e.g. LP1/LP2) was associated with
hypercholesterolemia (~4.5 mM) at postnatal day 21 in both sexes. At this age, hepatic
Cyp7a1 expression in these offspring was reduced two thirds compared to control. This
is intriguing given that Cyp7a1 has been previously demonstrated to display maximal
expression at postnatal day 2147,

48

. A LP1/LP2-induced increase in circulating

cholesterol by three weeks of age is of considerable interest with regards to the early
development of cardiovascular disease. Interestingly, when a low protein diet was fed to
nursing mothers fostering control diet offspring, circulating cholesterol levels was not
significantly different, highlighting the importance of the in utero environment in the
long-term regulation of cholesterol levels. In LP2 offspring at day 130, circulating and
hepatic cholesterol was significantly higher (~30%) in the male LP2 offspring. The
decrease in Cyp7a1 is likely the major contributor to the observed 30% increase in
hepatic cholesterol given that there was no difference in the protein levels of Hmg-CoA
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reductase (involved in cholesterol synthesis) and the LDL receptor (involved in
cholesterol flux).
The augmented circulating and hepatic cholesterol observed in these LP2 offspring is
similar to what is observed in Cyp7a1-deficient mice and in humans with a mutation in
CYP7A149, 50. This elevation in baseline cholesterol in combination with other diet and
lifestyle factors (i.e. high fat diet) could make these animals more susceptible to
hypertension and cardiovascular disease. For example, LP2 female offspring that were
fed a control diet higher in carbohydrates after lactation exhibited elevated systolic blood
pressure at 1 year of age40. Although males were not examined in that study, it remains
possible from our study that the augmented cholesterol from as early as three weeks
could collectively contribute to a similar or worse phenotype. Moreover, the combination
of impaired glucose tolerance38, visceral obesity36, and augmented cholesterol in these
LP2 offspring would lead towards the development of metabolic syndrome.
It is interesting to note that while LP2 offspring had augmented cholesterol at day 130,
neither LP1 or LP3 offspring exhibited this phenotype. This is likely due to the fact that a
low protein environment during development results in adaptations that are better suited
to a similar environment later on in life51. Therefore, when a switch is made to a 20%
protein diet after liver development52 (e.g. LP2), the offspring become more susceptible
to physiological disorders. It was surprising to find that the LP3 animals had normal
circulating cholesterol in our study, given previous work which has demonstrated that
rapid catch-up growth in humans is more tightly associated with components of the
metabolic syndrome53. The answer may be due to the differences in liver development
and the duration of the low protein insult. Liver development in rodents and humans
consists of embryonic cell specification, budding, and then differentiation 52. In rodents,
liver differentiation develops later in gestation with a large portion of it occurring in
postnatal life. In contrast, liver differentiation in humans already occurs in early to midgestation52. Therefore, at birth the rat liver is ‘less’ mature and has greater plasticity than
the human liver. This makes the rat liver more susceptible to further insult or recovery
during that period of neonatal life. This plasticity in liver development is evident in the
LP3 offspring whereby Cyp7a1 expression was restored at postnatal day 21 due to
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increases in LXR activation. This is in contrast to the LP2 offspring, which did not
exhibit alterations in LXR binding to the Cyp7a1 promoter. Collectively, this would
suggest that it is the difference in the duration of the dietary low protein insult (LP2 = 43
days versus LP3 = 21 days) throughout the crucial stages of rat liver development that
likely plays a greater role in long-term liver impairment than catch-up growth.
Epigenetic mechanisms have been previously demonstrated to underlie developmental
programming of gene transcription. However, investigation of the epigenetic mechanisms
linking an in utero insult to the development of disease in postnatal life is limited18, 19, 23,
24

. Since a conserved CpG island is not found in the promoter region of the human and

rodent Cyp7a1, it is more likely that posttranslational histone modifications may
influence its long-term expression compared to DNA methylation. In the present study,
significant decreases in the acetylation and increases in methylation of histone H3 [K9],
promoting a repressive chromatin environment, was observed surrounding the hepatic
Cyp7a1 promoter in LP2 male offspring at postnatal day 21. This persisted into adulthood
(day 130), long after the switch to a control diet. The observed repressive chromatin
environment correlated with decreased recruitment of RNA Polymerase II, diminished
Cyp7a1 protein levels, and the observed increases in circulating cholesterol. This is not
surprising as trichostatin A (TSA), a histone deacetylase inhibitor, has been previously
demonstrated to increase Cyp7a1 expression and cholesterol metabolism when
administered in mice54. It is interesting to note that the significant increase in histone H3
trimethylation at postnatal days 21 was preceded by a decrease in the expression of the
lysine 9 demethylase Jmjd2a during fetal life. This suggests that an early loss of
demethylation in the fetal liver, due to a low protein diet, may initiate the enhanced
trimethylation of histone H3 observed in LP2 offspring.
While an increase in the acetylation of histone H3 [K9,14] was observed surrounding the
Cyp7a1 promoter at embryonic day 19, recruitment of RNA polymerase II to its promoter
and Cyp7a1 protein levels were modestly reduced. Moreover, increases in the overall
trimethylation of histone H3 (lysine 9) were not observed at this time in development.
Therefore in fetal life, the decreased expression of Cyp7a1 is likely also due to
transcriptional mechanisms. Recently, it was demonstrated that a low protein diet in mice
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led to decreased expression of LXRα and certain downstream target genes at embryonic
day 19.5 as a result of increased DNA methylation at LXRα promoter22. Therefore, the
decrease in recruitment of RNA polymerase II to the Cyp7a1 promoter in the fetuses
derived from a low protein diet could possibly be due to decreased recruitment of LXRα
at the Cyp7a1 LXRE site.
To date, very little is known about the links between malnutrition and epigenetic
mechanisms during development, specifically with regards to the regulation of histone
modifying enzymes. One study looking at fetal surfactant protein A (SP-A) expression
demonstrated that lower oxygen tension in vitro can promote alterations in these enzymes
leading to a repressive chromatin environment55. Given this low protein model leads to
asymmetric IUGR20, and that this brain-sparing effect is associated with fetal hypoxia56,
57

, this could conceivably mediate the observed decrease in JmjD2a expression. As a

result, this would lead to the observed hypermethylation and hypoacetylation surrounding
the promoter of Cyp7a1 during development.
Recent studies in animal models have suggested that perturbations to the maternal
environment during pregnancy can lead to sex-specific, long-term consequences in
postnatal life. For example, LP2 offspring exhibited insulin resistance42 and visceral
obesity36 exclusively in the adult male offspring at postnatal day 130. In this study,
circulating cholesterol increased while a concomitant decrease in Cyp7a1 protein levels
and RNA Polymerase II recruitment was observed only in the adult male offspring at
postnatal day 130. Furthermore, the male-specific silencing of Cyp7a1 expression
observed at day 130 was governed, in part, due to male-specific repressive changes in
posttranslational histone modifications surrounding the active site of the Cyp7a1
promoter. Given cholesterol and Cyp7a1 expression are misregulated in both sexes at day
21, but only in males at day 130, it is unlikely that imprinting is involved. Instead, it is
plausible that gender-specific hormonal differences after lactation may mediate these
programmed effects. It has been postulated that sex steroids (e.g estrogen) may offer the
female some protective effects against the development of these disease processes,
including elevated blood pressure58. Evidence from this comes from the aromatase
knockout (ArKO) mouse, which cannot synthesize endogenous estrogens due to
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disruption of the Cyp19 gene59. ArKO females when challenged with a high cholesterol
diet had higher circulating cholesterol and lower Cyp7a1 expression compared to wildtype females and males of either genotype59, where estrogen replacement reversed the
hepatic steatosis60. However, the stimulatory effects of synthesizing estrogen may be only
part of the reason for the sexual dimorphism observed in LP2 offspring. Given that LP2
males have suppressed levels of circulating testosterone compared to control males42, it is
conceivable that the loss of this male sex steroid may also underlie the male-specific
impairment of Cyp7a1 and cholesterol catabolism. Aside from sex steroids, another
important difference in LP2 males and females in that study was circulating basal insulin
concentrations. LP2 male offspring at postnatal day 130 have two-fold higher levels of
circulating insulin42, which has been previously demonstrated to inhibit Cyp7a1 in both
the rat hepatocytes and streptozotocin (STZ)-induced diabetic rats via decreases in the
binding of the transcription factors FoxO1 and Smad3 to the promoter of Cyp7a161.
Moreover, studies have now established that these hormones can influence
posttranslational histone modifications. For example, the estrogen receptor has been
demonstrated to bind to coregulators (i.e. CBP/p300, SRC-1, SRC-2) that enhance
promoter-specific histone H3 acetylation leading to an active chromatin state surrounding
the promoter regions of estrogen responsive genes62-64. Therefore in LP2 females, it is
conceivable that their ‘histone code’ was altered at the promoter of Cyp7a1 via the
actions of these hormones.
In conclusion, our results demonstrate that low protein diet-induced IUGR leading to
augmented cholesterol in postnatal life results from permanent epigenetic silencing of the
hepatic Cyp7a1 promoter, via posttranslational histone modifications. Moreover, our
study identifies the in utero environment as a novel risk factor for cholesterol
dysregulation, and aids our understanding of why a prevalence of metabolic syndromerelated diseases can be linked to adverse events in fetal life. Given the plasticity of the
liver in fetal and neonatal life, further studies will undoubtedly lead to early life dietary
and/or drug intervention strategies to lower cholesterol and reduce the incidence of the
metabolic syndrome in adulthood.

91

3.5

References

1. Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories.
Circulation 97, 1837-1847 (1998).
2. Mathieu, P., Pibarot, P. & Despres, J. P. Metabolic syndrome: the danger signal in
atherosclerosis. Vasc. Health. Risk Manag. 2, 285-302 (2006).
3. Jelinek, D. F., Andersson, S., Slaughter, C. A. & Russell, D. W. Cloning and
regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid
biosynthesis. J. Biol. Chem. 265, 8190-8197 (1990).
4. Repa, J. J. & Mangelsdorf, D. J. The role of orphan nuclear receptors in the regulation
of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16, 459-481 (2000).
5. Erickson, S. K. et al. Hypercholesterolemia and changes in lipid and bile acid
metabolism in male and female cyp7A1-deficient mice. J. Lipid Res. 44, 1001-1009
(2003).
6. LaRosa, J. C., He, J. & Vupputuri, S. Effect of statins on risk of coronary disease: a
meta-analysis of randomized controlled trials. JAMA 282, 2340-2346 (1999).
7. Brown, W. V. Safety of statins. Curr. Opin. Lipidol. 19, 558-562 (2008).
8. Lamarche, B., Lemieux, S., Dagenais, G. R. & Despres, J. P. Visceral obesity and the
risk of ischaemic heart disease: insights from the Quebec Cardiovascular Study. Growth
Horm. IGF Res. 8 Suppl B, 1-8 (1998).
9. Ross, M. G. & Beall, M. H. Adult sequelae of intrauterine growth restriction. Semin.
Perinatol. 32, 213-218 (2008).
10. Chiarelli, F., di Ricco, L., Mohn, A., De Martino, M. & Verrotti, A. Insulin resistance
in short children with intrauterine growth retardation. Acta Paediatr. Suppl. 88, 62-65
(1999).

92

11. Jaquet, D., Gaboriau, A., Czernichow, P. & Levy-Marchal, C. Insulin resistance early
in adulthood in subjects born with intrauterine growth retardation. J. Clin. Endocrinol.
Metab. 85, 1401-1406 (2000).
12. Karlberg, J. P., Albertsson-Wikland, K., Kwan, E. Y., Lam, B. C. & Low, L. C. The
timing of early postnatal catch-up growth in normal, full-term infants born short for
gestational age. Horm. Res. 48 Suppl 1, 17-24 (1997).
13. Barker, D. J., Martyn, C. N., Osmond, C., Hales, C. N. & Fall, C. H. Growth in utero
and serum cholesterol concentrations in adult life. BMJ 307, 1524-1527 (1993).
14. Barker, D. J., Bull, A. R., Osmond, C. & Simmonds, S. J. Fetal and placental size and
risk of hypertension in adult life. BMJ 301, 259-262 (1990).
15. Napoli, C. et al. Influence of maternal hypercholesterolaemia during pregnancy on
progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in
Children (FELIC) study. Lancet 354, 1234-1241 (1999).
16. Burns, S. P. et al. Gluconeogenesis, glucose handling, and structural changes in livers
of the adult offspring of rats partially deprived of protein during pregnancy and lactation.
J. Clin. Invest. 100, 1768-1774 (1997).
17. Ozanne, S. E., Smith, G. D., Tikerpae, J. & Hales, C. N. Altered regulation of hepatic
glucose output in the male offspring of protein-malnourished rat dams. Am. J. Physiol.
270, E559-64 (1996).
18. Rees, W. D., Hay, S. M., Brown, D. S., Antipatis, C. & Palmer, R. M. Maternal
protein deficiency causes hypermethylation of DNA in the livers of rat fetuses. J. Nutr.
130, 1821-1826 (2000).
19. Lillycrop, K. A., Phillips, E. S., Jackson, A. A., Hanson, M. A. & Burdge, G. C.
Dietary protein restriction of pregnant rats induces and folic acid supplementation
prevents epigenetic modification of hepatic gene expression in the offspring. J. Nutr. 135,
1382-1386 (2005).

93

20. Desai, M. & Hales, C. N. Role of fetal and infant growth in programming metabolism
in later life. Biol. Rev. Camb. Philos. Soc. 72, 329-348 (1997).
21. Zhang, J., Lewis, R. M., Wang, C., Hales, N. & Byrne, C. D. Maternal dietary iron
restriction modulates hepatic lipid metabolism in the fetuses. Am. J. Physiol. Regul.
Integr. Comp. Physiol. 288, R104-11 (2005).
22. van Straten, E. M. et al. The liver X-receptor gene promoter is hypermethylated in a
mouse model of prenatal protein restriction. Am. J. Physiol. Regul. Integr. Comp. Physiol.
298, R275-82 (2010).
23. Raab, E. L., Vuguin, P. M., Stoffers, D. A. & Simmons, R. A. Neonatal exendin-4
treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine
growth-retarded rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297, R1785-94
(2009).
24. Burdge, G. C., Hanson, M. A., Slater-Jefferies, J. L. & Lillycrop, K. A. Epigenetic
regulation of transcription: a mechanism for inducing variations in phenotype (fetal
programming) by differences in nutrition during early life? Br. J. Nutr. 97, 1036-1046
(2007).
25. Shilatifard, A. Chromatin modifications by methylation and ubiquitination:
implications in the regulation of gene expression. Annu. Rev. Biochem. 75, 243-269
(2006).
26. Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074-1080
(2001).
27. Park, J. H., Stoffers, D. A., Nicholls, R. D. & Simmons, R. A. Development of type 2
diabetes following intrauterine growth retardation in rats is associated with progressive
epigenetic silencing of Pdx1. J. Clin. Invest. 118, 2316-2324 (2008).
28. Chomczynski, P. & Sacchi, N. Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159
(1987).

94

29. Hardy, D. B., Janowski, B. A., Corey, D. R. & Mendelson, C. R. Progesterone
receptor plays a major antiinflammatory role in human myometrial cells by antagonism
of nuclear factor-kappaB activation of cyclooxygenase 2 expression. Mol. Endocrinol.
20, 2724-2733 (2006).
30. Condon, J. C., Hardy, D. B., Kovaric, K. & Mendelson, C. R. Up-regulation of the
progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear
factor-kappaB may contribute to the onset of labor through inhibition of PR function.
Mol. Endocrinol. 20, 764-775 (2006).
31. Chakrabarti, S. K., James, J. C. & Mirmira, R. G. Quantitative assessment of gene
targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of
chromatin structure in directing promoter binding. J. Biol. Chem. 277, 13286-13293
(2002).
32. Chiang, J. Y., Kimmel, R. & Stroup, D. Regulation of cholesterol 7alpha-hydroxylase
gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 262, 257265 (2001).
33. Gibbs, R. A. et al. Genome sequence of the Brown Norway rat yields insights into
mammalian evolution. Nature 428, 493-521 (2004).
34. Touster, O., Aronson, N. N.,Jr, Dulaney, J. T. & Hendrickson, H. Isolation of rat liver
plasma membranes. Use of nucleotide pyrophosphatase and phosphodiesterase I as
marker enzymes. J. Cell Biol. 47, 604-618 (1970).
35. Petrik, J. et al. A low protein diet alters the balance of islet cell replication and
apoptosis in the fetal and neonatal rat and is associated with a reduced pancreatic
expression of insulin-like growth factor-II. Endocrinology 140, 4861-4873 (1999).
36. Guan, H. et al. Adipose tissue gene expression profiling reveals distinct molecular
pathways that define visceral adiposity in offspring of maternal protein-restricted rats.
Am. J. Physiol. Endocrinol. Metab. 288, E663-73 (2005).

95

37. Langley-Evans, S. C., Lilley, C. & McMullen, S. Maternal protein restriction and
fetal growth: lack of evidence of a role for homocysteine in fetal programming. Br. J.
Nutr. 96, 578-586 (2006).
38. Chamson-Reig, A., Thyssen, S. M., Arany, E. & Hill, D. J. Altered pancreatic
morphology in the offspring of pregnant rats given reduced dietary protein is time and
gender specific. J. Endocrinol. 191, 83-92 (2006).
39. Langley-Evans, S. C. Critical differences between two low protein diet protocols in
the programming of hypertension in the rat. Int. J. Food Sci. Nutr. 51, 11-17 (2000).
40. Petry, C. J., Ozanne, S. E., Wang, C. L. & Hales, C. N. Early protein restriction and
obesity independently induce hypertension in 1-year-old rats. Clin. Sci. (Lond) 93, 147152 (1997).
41. McMullen, S. & Langley-Evans, S. C. Maternal low-protein diet in rat pregnancy
programs blood pressure through sex-specific mechanisms. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 288, R85-90 (2005).
42. Chamson-Reig, A., Thyssen, S. M., Hill, D. J. & Arany, E. Exposure of the pregnant
rat to low protein diet causes impaired glucose homeostasis in the young adult offspring
by different mechanisms in males and females. Exp. Biol. Med. (Maywood) 234, 14251436 (2009).
43. Petry, C. J., Ozanne, S. E. & Hales, C. N. Programming of intermediary metabolism.
Mol. Cell. Endocrinol. 185, 81-91 (2001).
44. Crosby, W. M. Studies in fetal malnutrition. Am. J. Dis. Child. 145, 871-876 (1991).
45. Greengard, O., Federman, M. & Knox, W. E. Cytomorphometry of developing rat
liver and its application to enzymic differentiation. J. Cell Biol. 52, 261-272 (1972).
46. Gruppuso, P. A. et al. Modulation of mitogen-independent hepatocyte proliferation
during the perinatal period in the rat. In Vitro Cell. Dev. Biol. Anim. 33, 562-568 (1997).

96

47. Ness, G. C. Developmental regulation of the expression of genes encoding proteins
involved in cholesterol homeostasis. Am. J. Med. Genet. 50, 355-357 (1994).
48. Massimi, M., Lear, S. R., Huling, S. L., Jones, A. L. & Erickson, S. K. Cholesterol
7alpha-hydroxylase (CYP7A): patterns of messenger RNA expression during rat liver
development. Hepatology 28, 1064-1072 (1998).
49. Erickson, S. K. et al. Hypercholesterolemia and changes in lipid and bile acid
metabolism in male and female cyp7A1-deficient mice. J. Lipid Res. 44, 1001-1009
(2003).
50. Pullinger, C. R. et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency
has a hypercholesterolemic phenotype. J. Clin. Invest. 110, 109-117 (2002).
51. Simmons, R. Developmental origins of adult metabolic disease: concepts and
controversies. Trends Endocrinol. Metab. 16, 390-394 (2005).
52. Kung, J. W., Currie, I. S., Forbes, S. J. & Ross, J. A. Liver development,
regeneration, and carcinogenesis. J. Biomed. Biotechnol. 2010, 984248 (2010).
53. Eriksson, J. G. et al. Catch-up growth in childhood and death from coronary heart
disease: longitudinal study. BMJ 318, 427-431 (1999).
54. Mitro, N. et al. Insights in the regulation of cholesterol 7alpha-hydroxylase gene
reveal a target for modulating bile acid synthesis. Hepatology 46, 885-897 (2007).
55. Islam, K. N. & Mendelson, C. R. Permissive effects of oxygen on cyclic AMP and
interleukin-1 stimulation of surfactant protein A gene expression are mediated by
epigenetic mechanisms. Mol. Cell. Biol. 26, 2901-2912 (2006).
56. Lackman, F., Capewell, V., Gagnon, R. & Richardson, B. Fetal umbilical cord
oxygen values and birth to placental weight ratio in relation to size at birth. Am. J. Obstet.
Gynecol. 185, 674-682 (2001).

97

57. Regnault, T. R. et al. Development and mechanisms of fetal hypoxia in severe fetal
growth restriction. Placenta 28, 714-723 (2007).
58. Ozaki, T., Nishina, H., Hanson, M. A. & Poston, L. Dietary restriction in pregnant
rats causes gender-related hypertension and vascular dysfunction in offspring. J. Physiol.
530, 141-152 (2001).
59. Hewitt, K. N., Boon, W. C., Murata, Y., Jones, M. E. & Simpson, E. R. The
aromatase knockout mouse presents with a sexually dimorphic disruption to cholesterol
homeostasis. Endocrinology 144, 3895-3903 (2003).
60. Hewitt, K. N., Pratis, K., Jones, M. E. & Simpson, E. R. Estrogen replacement
reverses the hepatic steatosis phenotype in the male aromatase knockout mouse.
Endocrinology 145, 1842-1848 (2004).
61. Li, T., Ma, H. & Chiang, J. Y. TGFbeta1, TNFalpha, and insulin signaling crosstalk
in regulation of the rat cholesterol 7alpha-hydroxylase gene expression. J. Lipid Res. 49,
1981-1989 (2008).
62. Leader, J. E., Wang, C., Popov, V. M., Fu, M. & Pestell, R. G. Epigenetics and the
estrogen receptor. Ann. N. Y. Acad. Sci. 1089, 73-87 (2006).
63. Hanstein, B. et al. P300 is a Component of an Estrogen Receptor Coactivator
Complex. Proc. Natl. Acad. Sci. U. S. A. 93, 11540-11545 (1996).
64. Kraus, W. L. & Kadonaga, J. T. P300 and Estrogen Receptor Cooperatively Activate
Transcription Via Differential Enhancement of Initiation and Reinitiation. Genes Dev. 12,
331-342 (1998).

98

4

NUTRITIONAL MISMATCH IN POSTNATAL LIFE OF LOW

BIRTH WEIGHT RAT OFFSPRING LEADS TO INCREASED
PHOSPHORYLATION OF HEPATIC EUKARYOTIC INITIATION
FACTOR 2 IN ADULTHOOD3

3

The material in this chapter is based on a manuscript accepted (METABOLISM-D-13-00099): Sohi G,
Revesz A, Hardy DB Nutritional Mismatch in Postnatal Life of Low Birth Weight Rat Offspring Leads to
Increase Phosphorylation of Hepatic Eukaryotic Initiation Factor 2  in Adulthood.(2013)
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4.1

Introduction

Adverse events during development can be linked to an increased risk for developing
obesity, cardiovascular disease (CVD) and diabetes. The “Predictive Adaptive Response”
hypothesis suggests that these adverse events would induce fetal adaptations that result in
a “survivor phenotype” which is advantageous in a similar predictive future reproductive
environment1. However, if there is a ‘mismatch’ to this predictive environment, these
adaptations would lead to a “thrifty phenotype” which is maladaptive2, 3. Clinically,
preterm infants that exhibited catch-up growth due to higher nutrient exposure have
increased markers of the metabolic syndrome by adolescence4-8. Similarly, in
experimental rodent models leading to low birth weight, accelerated postnatal growth
rates

due

to

overfeeding

is

associated

with

hypertension9,

obesity10,

hypercholesterolemia11, insulin resistance10 and reduced longevity12While the link
between impaired fetal growth and the risk for developing chronic disease in adulthood is
undoubtedly strong, the underlying mechanisms are still being elucidated. Some of these
mechanisms include epigenetics, alterations in transcription factor (i.e. nuclear receptors)
activity, mitochondrial dysfunction and impaired organogenesis13, 14
Another mechanism underlying the development of the metabolic syndrome in low
birth weight offspring may be due to impairment of protein synthesis. Protein synthesis is
considered critical for normal growth and has been associated with risk factors that
contribute to onset of metabolic diseases. For example, obese male subjects complicated
with type 2 diabetes have lower rates of whole-body protein synthesis15. Moreover,
guinea pigs with hypercholesterolemia exhibit decreased protein synthesis in the heart,
brain, kidney and liver16. In metazoans, protein translation is known to be negatively
regulated at the initiation stage by increases in the phosphorylation of eukaryotic
initiation factor (eIF)-2 at Serine (Ser) 51 residue17,

18

. Interestingly, in vitro studies

provide robust evidence for an inverse correlation between phosphorylation of eIF2
(Ser51) and phosphorylation of Akt1 (Ser473), a marker of insulin sensitivity19-22. To
address this relationship in the context of insulin signaling, a study by Achard and Labutt
using HepG2 human hepatoma cells demonstrated that palmitate treatment increased
phospho-eIF2α (Ser51) within 1 hour and decreased phospho-Akt1 (Ser473) in response
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to insulin simulation 18 hours later22. Yet, the link between phosphorylation of eIF2 to
phosphorylation of Akt1 (Serine 473) has not been fully examined in a physiological
context (i.e. maternal nutrition) in vivo. Moreover, little is known about how a nutritional
mismatch between fetal and neonatal life would influence these two established markers
of protein translation and insulin resistance.
The maternal protein restriction (MPR) rat model has been extensively studied to
support the “predictive adaptive response” hypothesis. For instance, low birth weight
offspring derived from MPR have a reduced lifespan when recuperated under a normal
protein diet at birth or after weaning23, 24. On the other hand, in the absence of protein
restoration, rat offspring tend to live longer24. A reduction in longevity can be attributed
to an earlier onset of metabolic risk factors in these intrauterine growth restricted (IUGR)
offspring, including insulin resistance25-28. Our laboratory and others have previously
observed impaired liver function to be associated with elevated hepatic cholesterol,
glucose and oxidative stress in MPR offspring25, 29, 30. Given that impaired liver function
is a key contributor to the etiology of the metabolic syndrome, we chose to examine
whether these MPR offspring receiving nutritional mismatch exhibit increases in hepatic
phosphorylation of eIF2 (Ser51) in postnatal life. In addition, we sought to determine
whether this corresponded with decreases in phosphorylation of Akt1 (Ser473) in vivo.
Moreover, given that the phosphorylation of eIf2 (Ser51) is also increased in response
to endoplasmic reticulum (ER) stress, which is associated with the metabolic syndrome3133

, we aimed to measure markers of hepatic ER stress (Glucose regulated protein 78/94

and spliced Xbp1) in these MPR offspring. To address these questions, three separate
dietary regimes were employed in pregnant rats. These include a normal (20%) protein
diet administered throughout life (control), a low (8%) protein diet throughout life (LP1),
until weaning (LP2), or exclusively prenatally (LP3).

4.2
4.2.1

Materials and Methods
Animals and Dietary Regimes

All procedures were performed in accordance with the guidelines set by the Canadian
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Council of Animal Care and upon approval of the Animal Care Committee of the
University of Western Ontario. Female and male Wistar rats at breeding age (250 g; 8-10
weeks old) were purchased from Charles River (La Salle, St. Constant, Quebec, Canada).
These rats were housed in individual cages and maintained at room temperature on a 12-h
light, 12-h dark cycle. For 3 weeks, these rats were left to acclimatize to the animal care
facility, and their reproductive cycles were followed. At the onset of proestrus, these rats
were mated. Impregnation was confirmed by the presence of sperm in the vaginal smear
the next morning. Upon confirmation of impregnation (gestation day 1), the rats were fed
either a control diet containing 20% protein (Bio-Serv, Frenchtown, NJ, USA, Product#
F4576 – Rodent Diet, AIN-93G, Blue, ½” pellets) or a LP diet containing 8% protein
(Bio-Serv, Frenchtown, NJ, USA, Product#F4575 – Rodent Diet, AIN-93G, ½” pellets).
The LP diet contained similar fat content and was made isocaloric (3.61 kcal/gram for
control and 3.66 kcal/gram for LP diet) by the addition of carbohydrates (Bio-Serv,
Frenchtown, NJ, USA). At birth, the litter size was reduced to 8 animals (4 females and 4
males), with weights closest to the litter mean. This ensured a standard litter size for all
mothers and no overnutrition. Three different dietary regimes were administered to these
offspring (Figure 4.1A). Offspring derived from a maternal LP diet were either
administered the LP diet throughout postnatal life (LP1), until the end of weaning (LP2),
or exclusively prenatally (LP3). Food and water was provided ad libitum, and food
intake was recorded during pregnancy and in the offspring. For consistency, only male
offspring were used for the study because early-life programming is known to occur in a
sexually dimorphic manner34, which was not the focus of this study. At embryonic day 19
(e19), 16 pregnant rats (8 control and 8 low protein diet pregnancies) were sacrificed and
the fetal livers were excised and snap frozen for immunoblot analysis. Another subset of
24 rats (8 control and 16 low protein diet pregnancies) were allowed to deliver
spontaneously. The food intake of these offspring were monitored by measuring their
food consumption every third day, and have been previously published25. At postnatal
day 130 (d130), 8 pups, each representing a single offspring from a different mother,
were sacrificed per dietary regime (control, LP1, LP2 and LP3) and the medial lobe liver
tissue was excised and frozen for quantitative RT-PCR and immunoblot analysis.
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4.2.2

Postnatal Growth Rate Analysis

From parturition to postnatal day 130, offspring body weights were recorded daily. The
growth curves for the four dietary regimes were obtained by plotting average body
weight (grams) ± the SEM against time (days). The growth curves displayed a best fit to
a sigmoidal curve with variable slope. Therefore, the data sets were analyzed under nonlinear regression using GraphPad Prism 5. The steepness of the curve was determined
by the slope factor value, which in this study reflected growth rate of the offspring.

4.2.3

Real Time PCR Analysis

Total RNA from Wistar rat medial lobe liver tissue was extracted at e19 and postnatal
d130 by the one-step method of Chomczynski and Sacchi (Trizol, Invitrogen, Carlsbad,
CA) 226. RNA was treated with deoxyribonuclease to remove any contaminating DNA. Of
the total RNA, 4g were reverse transcribed to cDNA using random primers and
Superscript II RNase H-reverse transcriptase (Invitrogen). Primer sets directed against
total rat Xbp-1 forward (5’-CTCAGAGGCAGAGTCCAAGG-3’) and reverse (5’CTCTGGGGA-AGGACATTTGA-3’)

and

-actin

forward

(5’-

ACGAGGCCCAGAGCAAGA-3’) and reverse (5’-TTGGTTACAATGCCGTGTTCA3’) were generated via Primer Express software (PE Applied Biosystems, Boston, MA,
USA). The relative abundance of each transcript was determined by real-time quantitative
PCR as previously published25. For the quantitative analysis of mRNA expression, the
Bio-Rad CFX384 Real Time System was employed using the DNA binding dye IQ
SYBER green supermix (Bio-Rad, Mississauga, Ontario, Canada). The cycling
conditions were 50C for 2 min, 95C for 10 min, followed by 40 cycles of 95C for 15
sec, and 60C for 1 min. The cycle threshold was set at a level where the exponential
increase in PCR amplification was approximately parallel between all samples. All
primer sets produced amplicons of the expected size and sequence. We calculated the
relative fold changes using the comparative cycle times (Ct) method with -actin as the
reference guide. Over a wide range of known cDNA concentrations, all primer sets were
demonstrated to have good linear correlation (slope=-3.4) and equal priming efficiency
for the different dilutions compared with their Ct values (data not shown). Given that all
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primer sets had equal priming efficiency, the Ct values (primer internal control) for each
primer set were calibrated to the experimental samples with the lowest transcript
abundance (highest Ct value). The relative abundance of each primer set compared with
calibrator was determined by the formula, 2

Ct

, in which Ct is the calibrated Ct

value.

4.2.4

Quantitative Real Time PCR Analysis of Xbp-1 spliced
mRNA Levels

This assay was performed using modifications of previously published methods25,

35

.

Briefly, 4g of RNA reverse transcribed to cDNA was added to a tube of 3.5 mM MgCl2,
0.12 mM each of dNTP (A, T, G, C), 1 x PCR reaction buffer (-MgCl2) (Invitrogen), 0.15
M rat Xbp-1 primer forward (5’-GCTTGTGATTGAGAACCAGG-3’) and reverse
(5’AGGCTTGGTGTATACATGG-3’), 0.05 units/L Taq DNA Polymerase, Native
(Invitrogen). The mixture was incubate at 50C for 2min, 95C for 10 min, followed by 2
cycles of 95C for 15 sec, and 60C for 1 min. 2.25 units//L Pst1 restriction enzyme
(Invitrogen) was added to the reaction mixture for 2 hours to digest the double stranded
cDNA of unspliced Xbp-1. The remaining mixture containing the spliced Xbp1 cDNA
was used towards determining Xbp1-spliced mRNA levels via quantitative real-time PCR
analysis.

4.2.5

Preparation of Tissue Total Protein Extracts and Immunoblot
Analysis

Frozen Wistar rat liver tissue were homogenized in RIPA buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P40, 0.25% C24H39NaO4, supplemented
with 1mM NaV, 50mM NaF and 25mM C3H7O6PNa2.XH2O), and protease inhibitor
cocktail (Roche). The homogenate was sonicated using five pulses of 1 second each with
amplitude of 30 % (Misonix Sonicator 4000, Newtown, CT, USA). Following sonication,
the homegenate was centrifuged at 300 g for 15 min at 4C. The supernatant was retained
and centrifuged at 14000 rpm for 20 min at 4C. The supernatant was retained as the total
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cellular protein fraction. Equal concentrations of proteins normalized by colorimetric
BCA Protein Assay (Pierce Corp., Madison, WI, USA), were fractionated in gradient
polyacrylamide gels (Invitrogen) and transferred onto polyvinylidenedifluoride
membrane (Millipore). Blots were probed using p-eIF2α (S51) rabbit monoclonal
antibody (1:1000, Cell Signaling Technology, Danvers, MA, USA), eIF2α rabbit
polyclonal antibody (1:1000, Cell Signaling), p-Akt1 (S373) rabbit polyclonal antibody
(1:1000, Abcam Inc., Cambridge, MA), Akt-1 rabbit polyclonal antibody (1:1250,
Abcam), Kdel ER marker mouse monoclonal antibody (1:200, Santa Cruz Biotechnology
Inc., Santa Cruz, CA), and monoclonal horseradish peroxidase-conjugated -actin
(1:50000, Sigma-Aldrich Oakville, Ontario, Canada) diluted in 5% milk-1Tris-buffered
saline-Tween 20 buffer. Horseradish peroxidase-conjugated donkey antirabbit IgG
(1:10000, Jackson ImmunoResearch Laboratories, West Grove, PA) or horseradish
peroxidase-conjugated donkey antimouse IgG (1:5000, Jackson ImmunoResearch
Laboratories) diluted in 5% milk 1Tris-buffered saline-Tween 20 buffer were used as
the secondary antibodies, respectively. Immunoreactive bands were visualized using an
enhanced chemiluminescence detection system (Thermo Scientific, Waltham, MA,
USA).

4.2.6

Statistics

All results were expressed as the mean of arbitrary values ± the SEM. The significance of
differences (P  0.05) between mean values was evaluated using the unpaired Student’s t
test for results from growth profile data, quantitative RT-PCR, and immunoblot analysis.

4.3
4.3.1

Results
Overall Growth Rates are Greater for MPR Offspring Derived
from a Low Protein Diet Until Birth (LP3) or Weaning (LP2)

Offspring derived from all four dietary regimes (C, LP1-3) had a growth curve pattern
that matched a sigmoidal curve with variable slope and displayed an R2 value of 0.99
(Figure 4.1C). Maternal low protein diet derived low birth weight offspring which were
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recuperated under a normal protein diet until birth (LP3) or weaning (LP2) had a higher
overall growth rate when compared to those maintained on a low protein diet throughout
life (LP1) (Figure 4.1B). The overall growth rates were inferred by the slope factor values
(Figure 4.1C). When compared to the Control group, the growth rates of LP2 offspring
were significantly higher (p<0.05) and LP1 were significantly lower (p<0.01, Figure
4.1C). Interestingly, the overall growth rates of LP3 were identical to that of the Control
group, despite the fact that LP3 offspring were born low birth weight (Figure 4.1B, C).
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Figure 4.1: The effect of maternal protein restricted (MPR) dietary regimes on
growth profile in wistar rats. The growth profile was examined for A. the four separate
dietary regimes which include a normal (20%) protein diet administered throughout life
(Control) and a low (8%) protein diet administered throughout life (LP1), until weaning
(LP2) or exclusively prenatally (LP3), B. the body weight (grams) were plotted against
days in postnatal life and C. the slope factor value were determined under a non-linear
regression (non fit curve) by setting line of best fit to a sigmoidal curve with a variable
slope in GraphPad Prism 5. Results were expressed as the mean ± SEM. *, Significant
difference (P <0.05) compared to the Control group; n=14-22/group, where each n
represents a single offspring derived from a different mother.
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4.3.2

Offspring derived from a low protein diet until birth (LP3) or
weaning (LP2) exhibit increased phosphorylation of hepatic
eIF2α (Ser51) by postnatal day 130.

In this study, we observed that hepatic protein translation was inhibited exclusively in the
livers of adult maternal low protein diet derived IUGR offspring who recuperated under a
normal protein diet in postnatal life. These included offspring derived from a LP2 and
LP3 dietary regime, where significant increases in phosphorylation of eIF2 (Ser51)
were observed in the livers at postnatal day 130 compared to Control (Figure 4.2B, C).
Interestingly, in IUGR offspring subjected to protein restriction throughout pregnancy
and postnatal life (LP1), a significant decrease in phosphorylation of eIF2 (Ser51) was
observed in the livers at postnatal day 130 compared to Control (Figure 4.2A). In
addition, the phosphorylation levels of eIF2 (Ser51) inversely correlated with
phosphorylation levels of Akt1 (Ser473) with respect to LP1 and LP2 offspring (Figure
4.2A, B). This correlation was absent at postnatal day 130 in the LP3 offspring (Figure
4.2C).
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Figure 4.2: The effect of MPR dietary regimes on hepatic phosphorylated eIF2α
(Ser51) protein levels at d130. The effect of A. LP1, B. LP2 and C. LP3 dietary regimes
on phosphorylated protein kinase B (Akt1) at Serine 473, Akt1, eukaryotic initiation
factor 2 α (eIF2α) at Serine 51 and eIF2α protein levels in the livers of male offspring at
postnatal day 130. Relative p-Akt1 (S473), Akt1, p-eIf2α (S51) and eIf2α protein levels
were determined using Western blot analysis. Total protein was isolated and p-Akt1
(S473), Akt1, p-eIF2α (S51) and eIF2α protein were detected on a Western blot using pAkt1 (S473), Akt1, p-eIF2α (S51) and eIF2α primary antibody. Their protein levels were
quantified using densitometry and normalized to that of -actin protein levels. Results
were expressed as the mean ± SEM. *, Significant difference (P <0.05); n=5–7/group,
where each n represents a single offspring derived from a different mother.
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4.3.3

Phosphorylation of eIF2 (Ser51) protein levels were
unaltered by maternal protein restriction in the fetal livers at
embryonic day 19

Since an increase in phosphorylation of eIF2 (Ser51) was observed by adulthood in
MPR offspring that received a Control protein diet postpartum (LP3) or post-weaning
(LP2), we further pursued whether hepatic protein translation attenuation was exclusive
to adult life or was persistent from fetal life. At embryonic day 19, there were no changes
phosphorylated eIF2 (Ser51) protein levels (Figure 4.3). Moreover, hepatic phosphoAkt1 (Ser473) protein levels were also normal compared to the Control (Figure 4.3).
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Figure 4.3: The effect of MPR on phosphorylated eIF2α (Ser51) protein levels in
fetal livers at embryonic d19. The effect of maternal low protein diet on phosphorylated
protein kinase B (Akt1) at Serine 473, Akt1, eukaryotic initiation factor 2 α (eIF2α) at
Serine 51 and eIF2α protein levels in the fetal livers at embryonic day 19. Relative pAkt1 (S473), Akt1, p-eIf2α (S51) and eIf2α protein levels were determined using
Western blot analysis. Total protein was isolated and p-Akt1 (S473), Akt1, p-eIF2α (S51)
and eIF2α protein were detected on a Western blot using p-Akt1 (S473), Akt1, p-eIF2α
(S51) and eIF2α primary antibody. Their protein levels were quantified using
densitometry and normalized to that of -actin protein levels. Results were expressed as
the mean ± SEM. *, Significant difference (P <0.05); n=7/group, where each n represents
a single offspring derived from a different mother.
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4.3.4

Elevated ER chaperones in the livers of adult offspring
derived from a LP diet exclusively during pregnancy (LP3)
and during pregnancy and lactation (LP2)

Another marker indicating that the perinatal environment may lead to ER stress in
adulthood is through an increase in ER chaperone proteins. Adult offspring derived from
a LP diet exclusively during pregnancy (LP3) and during pregnancy and lactation (LP2)
resulted in elevated hepatic ER chaperones by postnatal day 130 (Figure 4.4B, C).
Specifically, there was a significant increase in ER chaperones Grp78 in the LP2 derived
offspring, and Grp94 in the LP3 derived offspring in adulthood compared to Control
(Figure 4.4B, C). Interestingly, LP1 derived offspring displayed no changes to ER
chaperone Grp94 and 78 protein levels (Figure 4.4A).
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Figure 4.4: The effect of MPR dietary regimes on hepatic ER chaperones protein
levels at d130. The effect of A. LP1, B. LP2 and C. LP3 dietary regimes on Glucose
regulatory protein 94 and 78 (Grp94 & Grp78) protein levels in the livers of male
offspring at postnatal day 130. Relative Grp94 and Grp78 protein levels were determined
using Western blot analysis. Total protein was isolated and Grp94 and Grp78 protein
were detected on a Western blot using KDEL primary antibody, which recognizes the
carboxyl terminus KDEL sequence of Grp94 and Grp78. Their protein levels were
quantified using densitometry and normalized to that of -actin protein levels. Results
were expressed as the mean ± SEM. *, Significant difference (P <0.05); n=5–7/group,
where each n represents a single offspring derived from a different mother.
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4.3.5

Increases in Xbp-1 spliced variant mRNA levels coincide
with the elevated ER chaperone protein levels and enhanced
phosphorylation of eIF2α (Ser51) in the livers of adult
offspring derived from LP2 and LP3 dietary regimes

The spliced variant Xbp-1 is a more potent form of Xbp-1 transcription factor which
activates a wide variety of genes involved with ER stress activation pathway, including
ER chaperone proteins36, 37. In this study, we observed an increase in spliced variant Xbp1 mRNA levels in the livers of LP2 and LP3 derived offspring in adulthood compared to
Control (Figure 4.5B, C). The increase in spliced Xbp-1 mRNA levels partially correlated
with the increase in protein levels of spliced Xbp-1 downstream transcriptional targets,
the ER chaperone proteins (Figure 4.4B, C). Moreover, spliced Xbp-1 mRNA levels in
the livers of LP1 derived offspring were unchanged, which correlates with no change to
ER chaperones Grp94 and 78 in these offspring (Figure 4.4A).
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Figure 4.5: The effect of MPR dietary regimes on hepatic Xbp-1 spliced variant
mRNA levels at d130. The effect of A. LP1, B. LP2 and C. LP3 dietary regimes on Xbox binding protein (Xbp-1) spliced variant mRNA levels in the livers of male offspring
at postnatal day 130 via quantitative RT-PCR analysis. RNA was extracted and reverse
transcribed for quantitative RT-PCR using primer specific for Xbp-1. Reverse transcribed
RNA was first amplified by Taq DNA Polymerase for two PCR cycles and then treated
with Pst1 restriction enzyme to allow for splicing of all unspliced Xbp-1 transcripts.
Quantitative RT-PCR was then performed to amplify exclusively the Xbp-1 spliced
transcript. The relative levels of each Xbp-1 spliced mRNA transcript were normalized to
that of the levels of each β-actin mRNA transcript. Results were expressed as the mean ±
SEM. *, Significant difference (P <0.05); n=7/group, where each n represents a single
offspring derived from a different mother.
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4.4

Discussion

In this study, we demonstrated that there is an increase in phospho-eIF2 (Ser51) in the
adult livers of IUGR rat offspring exclusively when they undergo accelerated growth
rates as a consequence of a nutritional protein mismatch. Moreover, when there is no
mismatch between fetal and postnatal nutrition, the IUGR offspring experience slower
growth rates and do not exhibit hepatic protein translation attenuation in adult life. This
further supports the central tenet of the ‘thrifty phenotype’ hypothesis that long-term
adverse metabolic effects are most apparent when there is a mismatch between early
nutritional deprivation and later nutritional affluence2, 3, 38. Collectively, this study helps
to identify appropriate dietary intervention strategies for reducing the incidence of the
metabolic syndrome in IUGR offspring by highlighting the beneficial effects of matching
the prenatal and postnatal environment to maintain protein translation in the liver. It is
conceivable that such strategies could reduce the long-term usage of drugs prescribed to
manage symptoms of the metabolic syndrome.
MPR derived IUGR offspring that recuperated under a normal protein diet post-weaning
(LP2) or postpartum (LP3) displayed accelerated growth rates compared to MPR
offspring maintained on a low protein diet throughout fetal and postnatal life (LP1).
These accelerated growth rates (i.e. those exhibited by LP2 and LP3 offspring) mirrored
decreases in hepatic protein translation as reflected through increases in phospho-eIF2
(Ser51) levels. Conversely, slower growth rates due to an absence of a nutritional
mismatch (e.g. LP1) resulted in a decrease in phospho-eIF2 (Ser51) in adulthood. Since
no change was observed in the levels of hepatic phospho-eIF2 (Ser51) at embryonic day
19, accelerated growth rates is likely the more significant contributing factor to protein
translation attenuation in adult life, as opposed to the direct actions of the low protein diet
itself during pregnancy. However, to provide further support for the “predictive adaptive
response” hypothesis, it would be of interest to investigate the effects of low protein diet
exclusively administered during lactation or post-lactation. Our previous studies have
suggested that a low protein diet exclusively in fetal life or during pregnancy and
lactation did not alter circulating cholesterol25, indicating that a longer fetal and neonatal
low protein insult is necessary for impaired hepatic function long-term. Interestingly, four
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serine/threonine protein kinases have been identified to phosphorylate eIF2. These
include general control nonrepressed 2 kinase (GCN2), heme-regulated inhibitor kinase
(HRI), double stranded RNA-activated kinase (PKR) and protein kinase RNA-like
endoplasmic reticulum kinase (PERK) which are activated by amino acid depletion,
hypoxia, viral infection and accumulation of misfolded proteins, respectively17,

18

.

However, this study did not investigate whether these kinases were involved in increasing
levels of phospho-eIF2 (Ser51) observed in LP2 and LP3 offspring. Moreover, other
stages of protein synthesis regulation by important amino acid sensing modulators such
as through the mammalian target of rapamycin kinase (mTOR) were also not examined
but deserve consideration19.
Intriguingly, the LP2 and LP3 offspring display an accelerated growth rate despite
the observed increase in hepatic phospho-eIF2 (Ser51), an indicator of reduced protein
translation. The changes in growth occurred in spite of the fact that food intake was not
different between dietary groups25. Rather, this might be explained by changes in
adiposity since visceral fat mass and the fat to body weight ratio have been reported to be
twice as high in these LP2 offspring relative to the control26, 27. Therefore, it is plausible
that an increase in visceral obesity may predominantly underlie the increases in
accelerated growth (as assessed by bodyweight) in the LP2 and LP3 offspring, even
though the overall protein synthesis may be reduced in the liver. Interestingly, a decrease
in whole body protein synthesis has been previously reported in male type 2 diabetic
patients with obesity15. It is also noteworthy that even though the low birth weight LP2
offspring have a higher slope factor, reflecting higher overall growth rate, they do not
fully catch-up in size to the normal birth weight control offspring as they reach their
growth plateau sooner. With respect to the impact of phospho-eIF2 and on liver growth,
it is noteworthy the liver:body weight ratio was reduced 50% in LP offspring at
embryonic day 19 (when phospho-eIF2 was unchanged), they were caught up by day
13025. This suggests that the observed increases in phospho-eIF2 in LP2 and LP3
offspring at postnatal day 130 may occur after the liver has undergone differentiation and
growth.
An inability to induce protein translation is likely due to decreased insulin sensitivity in
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the liver34. In this study we observed an increase in phospho-Akt1 (Ser473) to be
associated with a decrease in phospho-eIF2 (Ser51) in LP1 offspring. Conversely, a
decrease in phospho-Akt1 (Ser473) was observed to be associated with an increase in
phospho-eIF2 (Ser51) in the LP2 offspring. This finding confirms previous in vitro
studies which have observed a bi-directional association between phosphorylated eIF2
(Ser51) and phosphorylated Akt1 (Ser473) by administering pharmacological inhibitors
of Akt1 and eIF219-22. Despite elevated phospho-eIF2 (Ser51) levels, the LP3
offspring did not display corresponding decreases in phospho-Akt1 (Ser473). This may
be due to the fact that some of the adverse effects of a low protein diet are rescued by
protein restoration during the first three weeks of neonatal life, a period of plasticity in
the developing rat liver46. It can be postulated that this correlation may eventually hold
true in the LP3 offspring later on in life provided phospho-eIF2 (Ser51) remain elevated
past day 130. Collectively, these results support the notion that elevated phospho-eIF2
(Ser51) could be contributing to a reduction in hepatic insulin sensitivity in LP2 and LP3
derived adult offspring. Interestingly, LP2 offspring have been previously demonstrated
to exhibit increases in HOMA-IR, glucose intolerance and decreases in hepatic
glucokinase activity27, 39. Alternatively, it remains to be determined whether a decrease in
phospho-eIF2 (Ser51) and slower growth rates in LP1 IUGR offspring is beneficial to
increasing hepatic glucokinase activity, insulin sensitivity, and glucose tolerance. It is
noteworthy that these LP1 offspring do live longer24.
Interestingly, protein translation attenuation via increases in phospho-eIF2 (Ser51) is
also one of the hallmark responses of elevated ER stress. ER stress is a result of excessive
accumulation of misfolded or unfolded proteins in the ER lumen due to a variety of
environmental insults40. The accumulation of these proteins triggers the activation of the
ER stress pathway, which is also referred to as the unfolded protein response (UPR)40.
UPR aims to alleviate ER stress by decreasing global protein translation in order to
reduce the load of the ER in processing these new proteins. In addition to a reduction of
global protein translation, there is also an increase in ER chaperone protein levels (i.e.
glucose regulated protein Grp78 and Grp94) to improve ER’s protein folding capacity36,
37

. Furthermore, ER stress induces the splicing of a highly conserved unconventional 26
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bp intron of the X-box binding protein 1 (Xbp-1) mRNA, which encodes for a potent
transcription factor involved with transcriptional upregulation of genes involved with
coping with the ER stress36,

37

. Collectively, an increase in phosphorylation of eIF2

(Serine 51), Grp94 and Grp78 protein levels, and splice variant XBP-1 mRNA level are
considered hallmark indicators of elevated ER stress. Given the critical role of
endoplasmic reticulum in overall cellular functions and survival, any stress to the ER
would therefore aggravate the symptoms associated with the metabolic syndrome. We
were interested in measuring these markers of UPR given ER stress has been
demonstrated to lead to aspects of the metabolic syndrome (insulin resistance, obesity
and hypercholesterolemia)31-33,

41

which are also exhibited in MPR offspring25-27. In

addition to increases in phospho-eIF2α (Ser51) in the adult livers of LP2 and LP3
offspring, we also observed increases in Xbp-1 splice variant mRNA levels. Since splice
variant Xbp-1 transcription factor is known to upregulate the transcription of ER
chaperones36,

37

, we expected corresponding increases in ER chaperones Grp78 and

Grp94 protein levels. However, in both LP2 and LP3 only one of the two ER chaperone
protein levels were significantly elevated. It is still noteworthy that the ER chaperone
Grp78, a downstream target gene of spliced Xbp-1, has been demonstrated to prevent an
increase in phospho-Akt1 (Ser473)42. Therefore the increase in hepatic spliced Xbp1
mRNA and Grp78 protein levels in the LP2 offspring may also help explain for our
observed decreases in hepatic phospho-Akt1 (Ser473) and the reported insulin resistance
in these offspring27.
In summary, we provide evidence that in addition to epigenetic and transcriptional
mechanisms underlying the ‘developmental origins of adult disease’, protein translation
attenuation may mediate long-term insulin resistance and other aspects of the metabolic
syndrome. Confirming the main tenets of the ‘thrifty hypothesis’, our results also
demonstrated that only in the situation whereby MPR offspring were faced with a protein
dietary mismatch from fetal to postnatal life did they display reduced hepatic protein
translation in adulthood. Moreover, these offspring were more susceptible to developing
insulin resistance and other markers of the metabolic syndrome as they displayed
indicators of elevated ER stress. The management of early life diet to reduce accelerated
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postnatal growth and improve hepatic protein synthesis in IUGR offspring may prove to
be an important intervention strategy to decrease the incidence of the metabolic syndrome
in adulthood.
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5.1

Introduction

Clinical studies have reported a strong correlation between low birth weight and
metabolic risk factors associated with cardiovascular disease (CVD)1-5. Therefore, the
likelihood of prescribing medication for the management of these metabolic symptoms
(e.g. statins for hypercholesterolemia) can be considered to be greater in these offspring.
This may be particularly relevant in cases of low birth weight offspring, which undergo
nutrition-induced accelerated growth in neonatal life and display an earlier onset of these
symptoms6-11. The underlying reason behind this phenomenon can be explained by the
“Predictive Adaptive Response” hypothesis, which suggests that adverse events during
development induce adaptations suited for survival in a similar predictive environment
but can become maladaptive if a ‘mismatch’ to the predictive environment occurs,
leading to a “thrifty phenotype”12-14. Clinically, this hypothesis has been supported by
evidence where accelerated growth due to higher nutrient exposure in preterm infants
results in an increase in markers of the metabolic syndrome by adolescence15-19.
However, very little is known about drug disposition of low birth offspring in adult life.
Moreover, the role of nutrition mismatch induced accelerated growth has not been
examined.

Several clinical and animal studies have observed liver dysfunction in postnatal life of
low birth weight infants20-24. Given that approximately 75% of prescribed drugs are
metabolized in the liver25, liver dysfunction may alter the pharmacokinetic parameters of
several drugs in postnatal life of these infants. Amongst the prescribed drugs eliminated
by the liver, three fourths of these are metabolized by the cytochrome P450 (CYP) family
of enzymes25. In humans, reduced intravenous midazolam clearance, a measure of hepatic
CYP3A4 activity, has been observed in preterm infants aged between 2 to 15 days26-28.
Interestingly, the CYP3A4 isozyme is responsible for the metabolism of approximately
half of all marketed drugs29. Yet, it remains to be investigated whether pharmacokinetics
of drugs in the liver are altered in adult life of low birth weight offspring.

Animal models make it feasible to investigate alterations in pharmacokinetics of a drug
due to changes in hepatic CYP enzyme activity. The long-term programming of Cyp3a
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activity was recently demonstrated by Tajima et. al. in mice offspring born of mothers
receiving a high fat diet during pregnancy30. Specifically, they correlated a decrease in
hepatic Cyp3a activity in six week old offspring with reduced triazolam substrate
clearance30. Although an important finding, it remains to be established whether similar
long-term programming of drug metabolizing CYP enzyme activities occur when in utero
insults result in low birth weight offspring. In rodent experimental models low birth
weight offspring that undergo accelerated growth rates due to a postnatal nutrition
mismatch

have

been

previously

associated

with

hypertension31,

obesity32,

hypercholesterolemia33, insulin resistance32 and reduced longevity34. Therefore, it would
be of interest to also determine the adverse consequences of altering the postnatal
nutrition environment of low birth weight offspring on long-term programming of hepatic
drug metabolizing CYP enzymes.
Since worldwide maternal under-nutrition is a leading source of impaired perinatal
development, and given amino acids play a critical role in fetal growth35, the maternal
protein restriction (MPR) dietary regime is a relevant animal model to study the
developmental origins of adult diseases (DOHaD). In addition, MPR shares features
common with placental insufficiency induced intrauterine growth restriction (PI-IUGR),
which occurs in 8% of pregnancies and produces protein deficiency in the developing
fetus36-38. We and others have previously demonstrated that maternal protein restriction
(MPR, 8% protein) during pregnancy and lactation results in low birth weight offspring
(asymmetrical IUGR

39

), which display impaired liver function in adulthood21-23, 40. In

addition, we have observed that these offspring display high circulating and hepatic
cholesterol levels exclusively when they are faced with a nutritional mismatch of a
normal (20%) protein diet post-weaning. This was attributed to the long-term repression
of a hepatic cytochrome P450 enzyme, cholesterol 7α-hydroxylase (Cyp7a1), which is
rate-limiting for the catabolism of cholesterol to bile acids41. It is noteworthy that
decreased Cyp7a1 expression is also associated with Endoplasmic Reticulum (ER) stress
in a rat model of hypothyroidism42. This is of great interest considering that we have
recently demonstrated that these MPR offspring have elevated ER stress markers in their
livers at four months of age42. In contrast, MPR derived offspring that were maintained
on a low protein diet throughout life did not display hypercholesterolemia or hepatic ER
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stress. As Cyp enzymes (i.e. Cyp3a1, Cyp3a2, Cyp2c11 and Cyp2b1) reside in the ER of
the liver and are the primary enzymes involved with Phase 1 of drug metabolism43, we
tested the hypothesis that MPR derived low birth offspring may have an impaired activity
of drug-metabolizing Cyp enzymes in adulthood when faced with a nutritional mismatch
in postnatal life. To address this, the effects of a low protein diet throughout life (LP1) or
until the end of lactation (LP2) were compared relative to a normal protein diet
throughout life of the offspring (C).

5.2
5.2.1

Materials and Methods
Animals and Dietary Regimes

All procedures were performed in accordance with the guidelines set by the Canadian
Council of Animal Care and upon approval of the Animal Care Committee of the
University of Western Ontario. Female and male Wistar rats at breeding age (250 g) were
purchased from Charles River (La Salle, St.Constant, Quebec, Canada). These rats were
housed in individual cages and maintained at room temperature on a 12-h light, 12-h dark
cycle. For 3 weeks, these rats were left to acclimatize to the animal care facility and their
reproductive cycles were followed. At the onset of proestrus, these rats were mated.
Impregnation was confirmed by the presence of sperm in the vaginal smear the next
morning. Upon confirmation of impregnation (gestation day 1), the rats were fed either a
control diet containing 20% protein (Bio-Serv, Frenchtown, NJ, USA, Product# F4576 –
Rodent Diet, AIN-93G, Blue, ½” pellets) or a LP diet containing 8% protein (Bio-Serv,
Frenchtown, NJ, USA, Product#F4575 – Rodent Diet, AIN-93G, ½” pellets). The LP diet
contained similar fat content and was made isocaloric by the addition of carbohydrates
(Bio-Serv, Frenchtown, NJ, USA). At birth, the litter size was reduced to eight animals
(four females and four males), with weights closest to the litter mean. This ensured a
standard litter size for all mothers. Three different dietary regimes were administered to
these offspring. Offspring derived from a maternal LP diet were either administered the
LP diet throughout postnatal life (LP1) or until the end of weaning (LP2). Food and water
was provided ad libitum, and food intake was recorded during pregnancy and in the
offspring. At embryonic day 19 (e19), a subset of pregnant rats were sacrificed and the
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fetal livers were excised and snap frozen for quantitative RT-PCR. Another subset of rats
was allowed to deliver spontaneously. The food intake of these offspring were monitored
by measuring their food consumption every third day, and have been previously
published41. At postnatal day 130 (d130), the pups were also sacrificed and the medial
lobe liver tissue was excised and frozen for quantitative RT-PCR and for testosterone
enzyme kinetics in liver microsomes via ultra performance liquid chromatography. We
did not examine the female offspring to prevent confounding factors related to their
estrous cycle and their hormonal profile. Moreover, the maternal low protein model has
been demonstrated to exhibit early life programming effects in a sexually dimorphic
manner, which was not the focus of this study41, 44, 45.

5.2.2

Real Time PCR Analysis

Total RNA from Wistar rat medial lobe liver tissue was extracted at e19 and d130 by the
one-step method of Chomczynski and Sacchi46 (TRIzol, Invitrogen, Carlsbad, CA, USA).
RNA was treated with deoxyribonuclease to remove any contaminating DNA. 4 µg of the
total RNA was reverse transcribed to cDNA using random primers and Superscript II
RNase H-reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Primer sets directed
against rat Cyp2b1, Cyp3a1, Cyp3a2, Cyp2c11, Car, Pxr, and β-actin were generated via
Primer Express software (PE Applied Biosystems, Boston, MA, USA) based on
published sequences (Table 5.1). The relative abundance of each transcript was
determined by real-time quantitative PCR as previously published47. For the quantitative
analysis of mRNA expression, the Bio-Rad CFX384 Real Time System was employed
using the DNA binding dye IQTM SYBR green supermix (Bio-Rad, Mississauga, Ontario,
Canada). The cycling conditions were 50 C for 2 min, 95 C for 10 min, followed by 45
cycles of 95 C for 15 sec and 60 C for 1 min. The cycle threshold was set at a level where
the exponential increase in PCR amplification was approximately parallel between all
samples. All primer sets produced amplicons of the expected size and sequence. We
calculated the relative fold changes using the comparative cycle times (Ct) method with
β-actin as the reference guide. Over a wide range of known cDNA concentrations, all
primer sets were demonstrated to have good linear correlation (slope=-3.4) and equal
priming efficiency for the different dilutions compared with their Ct values (data not
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shown). Given that all primer sets had equal priming efficiency, the ∆Ct values (primer
internal control) for each primer set were calibrated to the experimental samples with the
lowest transcript abundance (highest Ct value), and the relative abundance of each primer
set compared with calibrator was determined by the formula, 2∆∆Ct, in which ∆∆Ct is the
calibrated Ct value.

5.2.3

Hepatic Microsome Isolation

Wistar rat liver microsomes were isolated by differential centrifugation using methods
described previously by Velenosi et al.48. Briefly, 0.9% NaCl solution was used to rinse
liver tissue. The rinsed tissue was homogenized in 1.15% KCl solution containing 1 mM
EDTA and was centrifuged at 9000g for 20 min at 4°C. The subsequent supernatant was
centrifuged at 105, 000g for 60 min at 4°C. The microsomal pellet was resuspended in
100 mM potassium phosphate buffer containing 20% glycerol at pH 7.4 and protein
concentration was determined by colorimetric BCA Protein Assay (Pierce Corp.,
Madison, WI, USA). Microsomal protein extract was stored at -80°C for further analysis.

5.2.4

Hepatic Metabolism of Testosterone by Cyp3a, Cyp2b and
Cyp2c Enzymes

Metabolic activity of Cyp3a and Cyp2c in hepatic microsomes was determined using
methods previously described by Velenosi et al. (2012)48. Testosterone was selected as a
probe for Cyp3a, Cyp2b and Cyp2c enzyme activity based on previously documented
selective metabolism by specific rat P450 isozymes48, 49. 50 mM potassium phosphate
buffer and 2 mM MgCl2 (pH 7.4) with 1 mg/ml hepatic microsomal protein equating to a
final volume of 250l was used for timed enzymatic reactions. Linear rate of production
of metabolites was determined by varying time, protein and relevant substrate
concentrations prior to conducting enzymatic reactions. Formation of testosterone
metabolites (2–OH testosterone, 6-OH testosterone and 16-OH testosterone) was
determined to be linear at 10 minutes. The reactions were initiated by addition of 1mM
NADPH to microsomal samples containing varying concentrations of testosterone. The
reaction was terminated by addition of 50 l of ice-cold acetonitrile followed by 15minute incubation on ice and centrifugation to pellet precipitated protein48.
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5.2.5

Testosterone

Metabolite

Analysis

by

Ultraperformance

Liquid Chromatography with Photodiode Array (UPLC-PDA)
Detection
Testosterone metabolite analysis was performed by solid-phase extraction followed by
48

UPLC-PDA using methods previously described . The solid-phase extraction cartridge
(C18, Strata-X Polymeric Reverse Phase 33 m; Phenomenex, Torrance, CA) was
conditioned according to manufacturer’s specification. Carbamazepine was used as an
internal standard for testosterone quantification. The analytes and internal standard were
passed across the packing of the cartridge by gravity. The cartridges were then washed
with 1 ml of Milli-Q water followed by 1 ml of 50:50 methanol/water. 1 ml of methanol
containing 0.1% triethylamine and 0.1% trifluoroacetic acid was used to elute the
analytes into clean glass test tubes. The eluent was dried, reconstituted in mobile phase
and injected on a Phenomenex Kinetex C18 column (1.7 m particle size, 50 x 2.1 mm;
Torrence, CA) for testosterone and analyte separation. The column was maintained at
40°C in a Waters ACQUITY UPLC H-Class System. Mobile phase flow, gradient used
48

and detection wavelengths were the same as previously published .

5.2.6

Statistics

All results were expressed as the mean of arbitrary values  the standard error of the
mean (SEM). The significance of differences (p<0.05) between mean values were
evaluated using the unpaired Student’s t-test for ChIP and testosterone enzyme kinetics in
liver microsomes via ultra performance liquid chromatography. One-way analysis of
variance (ANOVA) followed by a Bonferroni’s Multiple Comparison post hoc test, was
used to evaluate significance of differences for results comparing the effect of all the
dietary regimes for qRT-PCR analysis.
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Table 5.1. Real Time PCR Primers
Gene

Primer (5’-3’)

Reference No.

Cyp3a1

FWD ACC AGT GGA AGA CTC AAG GAG ATG T

XM 003751127

REV TCA CAG GGA CAG GTT TGC CTT TCT

XM 003751127

FWD GCT CTT GAT GCA TGG TTA AAG ATT TG

BC 089765

REV ATC CAC AGA CCT TGC CAA CTC CTT

BC 089765

FWD CCC TGA GGA CTT TTG GGA TGG GC

BC 088146

REV GGG GCA CCT TTG CTC TTC CTC

BC 088146

FWD GCT CAA GTA CCC CCA TGT CG

XM 003750353

REV ATC AGT GTA TGG CAT TTT ACT GCG G

XM 003750353

FWD CCT TTT CCG TTC CCT GAC CA

AB 204900

REV AGG CAG AAC GTA GTG TTG AGT

AB 204900

FWD TGC ACA CAG GTT CCT GTT CCT GA

AF 151377

REV GGG GTG CGT GTC CTG GAT GC

AF 151377

FWD ACG AGG CCC AGA GCA AGA

NM 031144

REV TTG GTT ACA ATG CCG TGT TCA

NM 031144

Cy3a2

Cy2c11

Cy2b1

Car

Pxr

β-actin
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5.3
5.3.1

Results
A switch to a normal protein diet in postnatal life of MPR
derived low birth weight offspring leads to increases in
hepatic Cyp3a1, Cyp2c11 and Cyp2b1 mRNA expression at
postnatal day 130

In this study, we wanted to investigate the long-term effects of MPR derived low birth
weight offspring on expression and function of major drug metabolizing cytochrome
P450 (CYP) enzymes in the liver. Q-RT-PCR analysis was conducted to examine the
steady-state mRNA expression of hepatic Cyp3a1, Cyp3a2, Cyp2c11 and Cyp2b1 at
postnatal day 130. A 1.79, 1.45 and 1.94 fold increase in Cyp3a1, Cyp2c11, Cyp2b1
respectively was observed in the livers of MPR offspring who were placed on a normal
protein diet post-weaning (LP2) compared to the Control (Figure 5.1A, C, D).
Interestingly, in MPR offspring subjected to protein restriction throughout pregnancy and
postnatal life (LP1), there was no difference in hepatic Cyp3a1, Cyp3a2, Cyp2c11 and
Cyp2b1 mRNA expression (Figure 1A, B, C, D). Upon comparing the two MPR dietary
regimes, the LP2 offspring displayed a 1.93, 1.27 and 3.04 fold elevation in hepatic
Cyp3a1, Cyp2c11 and Cyp2b1 mRNA expression, respectively, relative to LP1 (Figure
1A, C, D). There was also a noticeable trend towards an increase in Cyp3a2 mRNA
expression in LP2 offspring compared to Control and LP1 offspring (P<0.06) (Figure
5.11B).
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.
Figure 5.1: Quantitative RT-PCR mRNA level analysis of A. Cyp3a1, B. Cyp3a2, C.
Cyp2c11, D. Cyp2b1 in the livers of rat offspring derived at postnatal d 130. RNA was
extracted and reverse transcribed for quantitative RT-PCR. mRNA level expression was
assessed via Q-RT-PCR using primers specific for Cyp3a1, Cyp3a2, Cyp2c11, and actin. The relative levels of each mRNA transcript were normalized to that of the levels
of each -actin mRNA transcript. Results were expressed as the mean ± SEM. * Control
vs LP2 Significant difference (P < 0.05), # LP1 vs LP2 Significant difference (P < 0.05);
n = 7–8/group, where each n represents an offspring derived from a different mother.
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5.3.2

Elevated Cyp3a1, Cyp2c11 and Cyp2b1 mRNA levels
correlated with increases in their drug metabolizing activity

To evaluate whether postnatal nutritional mismatch in MPR derived low birth weight
offspring also impacted long-term function of hepatic Cyp3a, Cyp2c and Cyp2b enzyme
activities, testosterone metabolism assay was performed using rat liver microsomes. This
assay is an excellent indicator of Cyp3a, Cyp2c and Cyp2b enzyme activity, as
testosterone metabolites 2OH-testosterone, 16OH-testosterone and 6OH-testosterone
have been previously observed to be generated by Cyp2c, Cyp2b and Cyp3a enzymes,
respectively48, 48. Full enzyme kinetics of these metabolites was determined for this study.
Vmax/Km, a measure of intrinsic clearance for 2OH-testosterone, 16OH-testosterone
and 6OH-testosterone, was significantly elevated by 2.0, 1.9 and 3.25 fold respectively
in LP2 offspring at postnatal day 130 (Figure 5.2 A, B, C). The increases in intrinsic
clearance of testosterone metabolites corresponded well with increases in Cyp2c11,
Cyp2b1 and Cyp3a1 mRNA expression, respectively (Figure 5.1D, C, A). The MichaelisMenten kinetic parameters for 2OH-testosterone, 16OH-testosterone and 6OHtestosterone are presented in Table 5.2.
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Figure 5.2: Michaelis-Menten plots of A. 2OH-testosterone, B. 16OH-testosterone
and C. 6OH-testosterone after incubation of rat liver microsomes with 1mM NADPH
and various concentrations of testosterone. Liver microsomes were extracted and timed
enzyme reaction was performed for testostereone metabolite analysis via solid-phase
extraction followed by UPLC-PDA. Each data point on the curves were expressed as the
mean ± SEM.; n = 5–6/group, where each n represents an offspring derived from a
different mother.
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Table 5.2. Michaelis-Menten kinetic values for P450 probe substrates in Control
and LP2 offspring rat liver microsomes at postnatal d 130
2α -OH Testosterone
Km

Vmax

Vmax/Km

(µM)

(pmol/min/mg protein)

(µl/min/mg protein)

Control

86 ± 19

500 ± 34

7.12 ± 1.17

LP2

50 ± 9

615 ± 38*

14.22 ± 2.48*

6β -OH Testosterone
Km

Vmax

Vmax/Km

(µM)

(pmol/min/mg protein)

(µl/min/mg protein)

Control

172 ± 18

182 ± 27

0.97 ± 0.16

LP2

123 ± 19

214 ± 21

1.85 ± 0.22**

16α -OH Testosterone
Km

Vmax

Vmax/Km

(µM)

(pmol/min/mg protein)

(µl/min/mg protein)

Control

80 ± 12

665 ± 58

8±2

LP2

43 ± 8*

873 ± 83

26 ± 6*

Data are presented as means ± SEM.
*P < 0.05 compared with control.
**P < 0.001 compared with control.
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5.3.3

Elevated Cyp3a1, Cyp2c11 and Cyp2b1 expression and
function coincided with increases in constitutive androstane
receptor (Car)

We next evaluated whether the elevated activity and steady-state mRNA levels of
Cyp3a1, Cyp2c11, Cyp2b1 coincided with upregulation of the orphan nuclear receptors
Car and Pxr. These nuclear receptors serve as master transcription factors which regulate
the transcription of several xenobiotic detoxification enzymes50. As depicted in Figure
5.3, administering a normal protein diet post-weaning to maternal low protein diet
derived low birth weight offspring (LP2) resulted in significantly increased expression of
hepatic Car mRNA levels compared to control in adulthood. This increase was prevented
in IUGR offspring maintained on a low protein diet throughout fetal and postnatal life
(LP1).
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Figure 5.3: Quantitative RT-PCR mRNA level analysis of A. Pxr and B. Car in the livers
of rat offspring derived at postnatal d 130. RNA was extracted and reverse transcribed for
quantitative RT-PCR. mRNA level expression was assessed via Q-RT-PCR using
primers specific for Pxr, Car and -actin. The relative levels of each mRNA transcript
were normalized to that of the levels of each -actin mRNA transcript. Results were
expressed as the mean ± SEM. *, Significant difference (P < 0.05); n = 7–8/group, where
each n represents an offspring derived from a different mother.
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5.3.4

Major hepatic drug metabolizing Cyp enzymes were
unaltered by MPR at postnatal day 21.

Since an increase in Cyp3a, Cyp2b and Cyp2c11 expression and activity was observed by
adulthood in MPR offspring that received a control protein diet post-weaning (LP2), we
further pursued whether this increase was exclusively due to a switch in diet postweaning or was persistent before the normal protein was restored at postnatal day 21.
Interestingly, MPR offspring displayed no significant difference in Cyp3a1, Cyp3a2,
Cyp2b1 and Cyp2c11 mRNA levels compared to control at postnatal day 21 (Figure 5.4).
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Figure 5.4: Quantitative RT-PCR mRNA level analysis of A. Cyp3a1, B. Cyp3a2, C.
Cyp2c11, D. Cyp2b1 in the livers of rat offspring derived at postnatal d 21. RNA was
extracted and reverse transcribed for quantitative RT-PCR. mRNA level expression was
assessed via Q-RT-PCR using primers specific for Cyp3a1, Cyp3a2, Cyp2c11, and actin. The relative levels of each mRNA transcript were normalized to that of the levels
of each -actin mRNA transcript. Results were expressed as the mean ± SEM. * Control
vs LP2 Significant difference (P < 0.05), # LP1 vs LP2 Significant difference (P < 0.05);
n = 7–8/group, where each n represents an offspring derived from a different mother.

141

5.4

Discussion

In this study we present the novel finding that MPR derived low birth weight rat
offspring have elevated Cyp3a, Cyp2b and Cyp2c activity in adulthood, exclusively when
faced with a nutritional mismatch in postnatal life. This was found to coincide with
increases in their steady-state mRNA levels, which may be due, in part, to transcriptional
induction by constitutive androstane receptor (Car). Interestingly, when low birth weight
offspring were maintained on a low protein diet post-lactation, they exhibited no
differences in expression of these Cyp enzymes. Collectively, this study suggests that
IUGR offspring receiving an inappropriate dietary intervention strategy may require an
adjustment to their drug dosages to effectively ameliorate the symptoms of the metabolic
syndrome. It is conceivable that adopting personalized drug treatment strategies in
postnatal life of low birth weight offspring may prove to be an effective therapeutic
approach.

Contrary to our initial hypothesis, administering a normal protein diet post-weaning to
maternal low protein diet derived low birth weight offspring (LP2) resulted in elevated
expression of drug metabolizing enzymes Cyp3a1 and Cyp2c11 in adulthood. The LP2
offspring displayed corresponding increases in intrinsic enzymatic activity of these Cyp
enzymes. Given that testosterone is also a substrate for these Cyp enzymes, it is
noteworthy that circulating testosterone has been previously reported to be decreased in
these LP2 offspring44. Our data now provide evidence for the mechanism underlying this
observation. Conversely, no differences in the steady-state mRNA expression of these
Cyp enzymes were observed when the IUGR offspring were maintained on a low protein
diet (LP1). Moreover, no changes in expression of these Cyp enzymes were observed at
postnatal day 21, which represents the end of lactation, a time point where normal protein
was restored for LP2 offspring. This suggests that the postnatal nutritional mismatch is
likely the more significant contributing factor to elevated Cyp3a1 and Cyp2c11
expression in adult life, as opposed to the direct actions of the low protein diet itself
during pregnancy and lactation. Since, increases in Cyp3a and Cyp2c activity correlated
with Cyp3a1 and Cyp2c11 steady-state mRNA expression in LP2 offspring, we
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postulated transcriptional mechanisms to underlie the increases in activity. Specifically,
we attempted to investigate the role of xenobiotic sensing nuclear receptors Pxr and Car
which represent major transcription factors involved with the transcriptional induction of
drug-metabolizing Cyp enzymes in humans51. In this study we observed an exclusive
elevation of Car mRNA levels in LP2 offspring. Interestingly, IUGR offspring
maintained on a low protein diet throughout fetal and postnatal life (LP1) displayed no
change in the xenobiotic sensing nuclear receptors Pxr and Car. Since, Car binding sites
have not been well characterized towards explaining the transcriptional induction of
Cyp3a1, Cyp3a2 and Cyp2c11 genes in rats, we evaluated whether increases in Car
correlated with the well characterized increases in Cyp2b1 expression41,

44, 45, 52-54

. As

anticipated, there was a noticeable increase in both hepatic Cyp2b1 mRNA and activity
levels in the LP2 adult offspring. Therefore, we propose that the increases in hepatic Car
expression also underlie the elevated expression and activity of Cyp3a1 and Cyp2c11 in
these offspring.
In support of the main tenet of the “predictive adaptive response” hypothesis, MPR
derived low birth weight rat offspring when faced with a nutritional mismatch, have been
previously reported to display high cholesterol, visceral obesity, hypertension, type 2
diabetes and reduced longevity55. Conversely, in the absence of protein restoration, rat
IUGR offspring have been observed to live longer42. Given that the liver plays a key role
in metabolism, any alterations in its function can lead to the development of the
metabolic syndrome and reduced lifespan. We recently observed elevated hepatic ER
stress exclusively in MPR derived IUGR offspring, which received a nutritional
mismatch in postnatal life56. Interestingly, an elegant study by Pascual et. al. in 2008
demonstrated that tunicamycin-induced ER stress in HepG2 cells induced the expression
of CYP2B6, the human ortholog of Cyp2b142. The molecular mechanism behind this
induction was attributed to ER stress activation of liver enriched activating transcription
factor 5 (ATF5), which shares close sequence homology to the more ubiquitously
expressed ATF4. ATF4 activation is known to occur via its selective translation during a
period of global protein translation attenuation due to elevated phosphorylation of
eukaryotic initiation factor 2. Therefore, it is possible that activation of ATF5 due to the
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previously observed hepatic increases in phosphorylation of eukaryotic initiation factor
256, may also cause the induction in Cyp2b1 expression observed in the study.
Interestingly, ATF5 has been observed to interact with C/EBP family of transcription
factors, as well as synergistically potentiate the actions of nuclear receptor Car, which are
both established regulators of the CYP2B6 gene57. With the use of Alggen PROMO
software, we have identified multiple putative C/EBP binding sites at the promoter of
all the Cyp enzymes examined in this study. Therefore, it is conceivable that under
conditions of high stress (i.e. ER stress), as exhibited in LP2 low birth weight offspring,
elevation of these xenobiotic metabolizing enzymes may serve as an adaptive response to
improve its detoxification capacity.

To date there have been no clinical studies conducted to evaluate the effects of low birth
weight on the pharmacokinetics of drugs in adulthood. This is particularly relevant to
drugs that would likely be used to manage the symptoms of the metabolic syndrome that
are observed in these offspring. For instance, despite strong clinical and animal evidence
linking IUGR to hepatic dysfunction and elevated cholesterol levels in adult life, there is
little known about whether statin pharmacokinetic or pharmacodynamic parameters are
altered. Out of all the statins that target the liver, simvastatin, lovastatin and atorvastatin
are metabolized primarily through CYP3A4, and fluvastatin is metabolized through
CYP2C957. Since, the rat orthologs of CYP3A4 (i.e. Cyp3a1 and Cyp3a2) and CYP2C11
(i.e. Cyp2c11) activity was elevated in adulthood, it is likely that low birth weight
offspring would metabolize statins in the liver at a faster rate. Our data suggest that low
birth weight offspring may require augmented doses of statins to maintain efficacy
towards reducing circulating cholesterol levels, a hypothesis which still remains to be
tested. Moreover, in order to completely understand the impact of low birth weight on
alterations in pharmacokinetics of drugs, several additional factors need to be evaluated,
mainly changes in plasma binding protein levels and drug transporter function. It is also
important to determine whether different insults leading to low birth weight would
similarly impact drug pharmacokinetic measures in adult life.
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In summary, this study highlights that low birth weight offspring faced with a nutritional
mismatch in postnatal life have elevated activity of major hepatic phase I drug
metabolizing enzymes in adulthood. Moreover, maintaining these low birth weight
offspring on a low protein diet prevented the increases in expression of these enzymes. It
is plausible that these offspring sense the nutritional mismatch as an unanticipated insult
and consequently respond by increasing their detoxification capacity via the activation of
nuclear receptor Car. In light of this study, careful consideration is recommended for
optimizing drug dosing to ameliorate symptoms of metabolic syndrome in IUGR
offspring that display nutritional mismatch induced accelerated growth.
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6.1
6.1.1

Summary and Discussion
Chapter Three

The aim of Chapter Three was to elucidate the molecular mechanisms which may lead to
long-term cholesterol dysregulation of MPR derived low birth weight offspring. Given
placental insufficiency in humans can produce protein deficiency in the fetus, this
maternal protein restriction model shares features in common with IUGR, which
represents 8% of newborns1-3. The hypothesis was that IUGR offspring may lead to
elevated cholesterol levels in adult offspring via repressive changes in histone
modifications at the Cyp7a1 promoter. As shown in Chapter Three, long-term hepatic
Cyp7a1 transcriptional repression in IUGR offspring derived from a low protein diet
during pregnancy and lactation underlies the increases in circulating and hepatic
cholesterol levels in both sexes at postnatal day 21 and exclusively in the male offspring
at postnatal day 130. This long-term repression in transcription was concomitant with
diminished acetylation and enhanced methylation of histone H3 [K9,14], markers of
chromatin silencing, surrounding the promoter region of Cyp7a1. These epigenetic
modifications originated in part due to diet-induced decreases in fetal hepatic Jmjd2a
expression, a histone H3 [K9] demethylase. This chapter provides the first evidence
highlighting the important role of epigenetic mechanisms (i.e. post-translational histone
modifications) in predisposing under nutrition derived low birth weight offspring to
increased risk of hypercholesterolemia. In addition, these findings overturn the dogma
that fetal programming effects are permanent since restoration of proteins in the maternal
diet during the neonatal period re-established the expression of Cyp7a1 to prevent
hypercholesterolemia. This restoration was associated with an increase in LXR
expression.

6.1.2

Chapter Four

The aim of Chapter Four was to determine whether nutritional mismatch in postnatal life
of low birth weight offspring would lead to elevated hepatic endoplasmic reticulum (ER)
stress in adulthood. The hypothesis was that MPR derived offspring faced with a

152

nutritional mismatch are at a higher risk of developing metabolic syndrome in adult life
due to presence of elevated hepatic ER stress. As shown in Chapter Four, exclusively
when MPR derived low birth weight offspring received a “nutritional mismatch”
postpartum, did they display elevated hepatic ER stress markers, including an increase in
X box binding protein 1 mRNA splicing levels and elevated ER chaperones (Glucose
regulated protein 78 and 94) at postnatal day 130. This was concomitant with attenuated
protein synthesis, as indicated by increased phosphorylation of eukaryotic initiation
factor 2 alpha at Serine 51 residue. Interestingly, maintaining the low birth weight
offspring on a low protein diet throughout life prevented hepatic ER stress. These
findings suggest that in addition to epigenetic and transcriptional mechanisms underlying
the ‘developmental origins of adult disease’, chronic activation of the ER stress pathway
may also mediate long-term insulin resistance and hypercholesterolemia.

6.1.3

Chapter Five

Given that low birth weight children that undergo accelerated growth display an earlier
onset of metabolic disease symptoms and are more likely to be prescribed medication to
manage their symptoms (e.g. statins for hypercholesterolemia), the aim of Chapter Five
was to investigate whether hepatic drug metabolism is altered in adult life of low birth
weight offspring. In addition, it was of interest to determine whether this association is
positively correlated in low birth offspring that display accelerated growth when faced
with a nutritional mismatch postpartum. The hypotheses was that MPR derived low birth
weight offspring may have an impaired ability to metabolize drugs in adulthood. As
shown in Chapter Five, a low protein diet during pregnancy and lactation leads to
increases in Cyp3a, Cyp2b and Cyp2c enzymatic activity (Vmax/Km) at postnatal day 130.
This was attributed primarily due to increases in mRNA levels of Cyp3a1, Cyp2b1 and
Cyp2c11. These elevated mRNA levels originate in part due to induction in expression of
constitute androstane receptor, which is known to activate gene transcription of these Cyp
enzymes. Interestingly, low birth weight offspring that were maintained on low protein
diet postpartum did not display any alterations in Cyp enzyme expression. Collectively,
these findings suggest that a low birth weight offspring when faced with a nutritional
mismatch postpartum may require greater doses of drugs, which are metabolized by
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Cyp3a, Cyp2b and Cyp2c enzymes, in order to exert their therapeutic effects. This is an
important finding as it is applicable to those individuals who are more likely to be
prescribed medication (e.g. statins for hypercholesterolemia) for the management of the
symptoms associated with the metabolic syndrome.

6.2

Future Directions

Chapter Three and Four of the thesis provide a mechanistic insight which improves our
understanding of why low birth weight babies are predisposed to increased risk of
metabolic syndrome. In identifying some of the underlying mechanisms, this thesis helps
identify early life dietary and/or drug intervention strategies which can be potentially
used to lower cholesterol and reduce the incidence of the metabolic syndrome. Such
strategies could reduce the long-term use of cholesterol lowering drugs in adulthood.
Moreover, considering that adults that were born low birth weight have a higher
likelihood of prescribing these drugs, chapter Five emphasizes the importance of
personalized pharmacological therapy in these individuals. However, upon collectively
analyzing the findings from the thesis, it is critical to realize that there are a number of
important questions that still need to be addressed. The following sections of the thesis
aim to highlight some of these important questions.

6.2.1

Molecular Mechanisms Underlying Sex-Specific Effects
observed in Adult Life of Low Birth Weight Offspring

These studies have demonstrated that elevated circulating cholesterol levels in LP2
offspring are associated with impaired Cyp7a1 expression in both sexes at three weeks
(pre-weaning) and exclusively in the males at four months of age4. This sex-specific
effect is consistent with findings from other animal model studies. For example, LP2
offspring exhibit insulin resistance5 and visceral obesity6 exclusively in the adult male
offspring at postnatal day 130. While the mechanisms underlying these sex-specific
programming effects have not been elucidated, it has been hypothesized that sex steroids
(i.e. estrogen) protect the female from the development of these disease processes,
including elevated blood pressure7. Evidence for this comes from the Aromatase
Knockout (ArKO) mouse, which cannot synthesize endogenous estrogens due to
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disruption of the Cyp19 gene8. ArKO females challenged with a high cholesterol diet
have higher circulating cholesterol levels and lower Cyp7a1 expression compared to
wild-type females and males of either genotype8. Moreover, estrogen replacement
reversed the hepatic steatosis in male ArKO mice9. Interestingly, this reversal is only
possible at lower doses of estrogen which are comparable to physiological levels in the
female rats as two previous studies have demonstrated a biphasic response of CYP7A1 to
estrogen levels in rats10,

11

. Lower doses of 17β Estradiol (an endogenous agonist)

resulted in an induction of CYP7A1 expression, while at higher doses there was a
repression of CYP7A1 expression. The molecular mechanism mediating this biphasic
dose response has not been fully elucidated yet. The effects of estrogen may only be part
of the reason for the sexual dimorphism, as a loss of circulating testosterone has been
previously observed in MPR males5. It is plausible that the loss of this androgen also
underlies male-specific impairment of Cyp7a1 and cholesterol catabolism. Elevated
activity of testosterone metabolizing Cyp3a, Cyp2b and Cyp2c enzymes observed in
adult life of MPR derived male offspring (Chapter 5) now provide evidence for the
mechanism underlying this observation. However, to pinpoint the role of these Cyp
enzymes in male specific decreases in circulating testosterone, their expression in MPR
females would need to be evaluated. In order to fully elucidate whether estrogen or
testosterone are protective towards preventing high cholesterol observed in MPR derived
adult male offspring, one can design in vivo experiments which involve castration of
MPR derived male offspring followed by a timely supplementation of estrogen or
testosterone. In conjunction, supplementing estrogen or testosterone in ovariectomized
MPR derived female offspring would also be considered to conclusively determine the
role of each hormone in the MPR derived male-specific impairment of cholesterol
homeostasis. It is also important to account for the role of other hormones in this
impairment. For instance, MPR male offspring at 130 days of age have two-fold higher
levels of circulating insulin5, which has been known to inhibit Cyp7a1 transcription in
both rat hepatocytes and streptozotocin (STZ)-induced diabetic rats via decreases in the
binding of transcription factors Fox01 and Smad3 to the promoter of Cyp7a112. Lastly,
studies have now demonstrated that sex steroid hormones can influence epigenetic
mechanisms, including post-translational histone modifications13. Therefore, future
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studies should evaluate whether alterations in the “histone code” due to endocrine
disruptions mediate these sex-specific effects. Conversely, the impact of the “histone
code” should also be examined in mediating these endocrine disruptions in low birth
weight offspring.

6.2.2

Role of Histone Modifying Enzymes in Initiating and
Maintaining Transcription of Genes Regulating Cholesterol
Homeostasis in Low Birth Weight Offspring

An imbalance of histone modifying enzymes can result in aberrant histone modification
levels in several disease processes. Consequently, these enzymes have gained a lot of
attention as potential therapeutic targets over the past decade14. Yet, no animal study has
attempted to examine changes to the global expression profiles of all known histone
modifying enzymes in placental insufficiency (PI) induced-IUGR. Two studies have
descriptively investigated changes to in vivo binding of a few histone modifying enzymes
in order to understand the post-translational histone modifications occurring at the
promoter region of pdx-1 in pancreatic -cells and glut-4 in skeletal muscles, which
underlie the development of type 2 diabetes in IUGR rat offspring15, 16. However, the role
of histone modifying enzymes in linking PI-IUGR to other risk factors of the metabolic
syndrome remains unexplored. The two main natural consequences of placental
insufficiency are low oxygen and nutrient delivery to the fetus, which can have an effect
on the expression and activity of histone modifying enzymes. For example, hypoxia has
been demonstrated to alter the expression and activity of a variety of histone modifying
enzymes17-21. Furthermore, hypoxia has been demonstrated to increase di-methylation of
Histone H3 K9 mediated by G9a methyltransferase22, an enzyme known to be involved
with bile acid mediated Cyp7a1 repression23. As MPR has been well documented to
result in placental insufficiency with low oxygen and nutrient deliver to the IUGR fetus2428

, a change in expression and activity of a wide variety of histone modifying enzymes

during development would be expected in this model. Furthermore, given that MPR
resulted in long-term repression of Cyp7a1, there is a need to examine the changes in
expression of histone modifying enzymes which result in stable repressive posttranslational histone modifications. Thus far, the steady-state mRNA levels of those [K9]
demethylases (Jmjd2a, Jmjd2b, Jmjd2c, Jmjd2d) that remove three methyl groups from
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[K9] of Histone H3 has been examined29. Q-RT-PCR revealed that a decrease in the
hepatic Jmjd2a mRNA was observed at e19 (data not shown). Furthermore, expression of
histone modifying enzymes needs to be correlated with their in vivo binding changes at
the promoter of Cyp7a1 with the use of ChIP. This would provide insight into their role
in establishing and maintaining the chromatin environment at Cyp7a1 promoter region
and in regulating long-term Cyp7a1 transcription. This role can be further strengthened
by performing in vitro studies by determining whether Cyp7a1 expression is altered due
to siRNA knockdown of the candidate histone modifying enzyme. The long-term goal
should be to further characterize the function of histone modifying enzymes in altering
long-term transcription of a wide variety of other cholesterol regulatory genes involved
with catabolism (Cyp8b1)30, efflux (ATP binding Cassette Transporters A1, G5 and
G8)31 and synthesis (Srebp-2)31 or uptake (LDL Receptor)31. This would lead to the
identification of key histone modifying enzymes that are more specific in prevention of
hypercholesterolemia. Additionally, it will be the first time research would be geared
towards investigating how a particular histone modifying enzyme plays a role in
influencing epigenetic mechanisms governing cholesterol regulation in general. A similar
approach can be implemented to investigate the role of histone modifying enzymes on
genes involved with glucose homeostasis. Moreover, the mRNA, protein and ChIP
library established from these experiments can be used for collaborative projects involved
with the investigation of the role of histone modifying enzymes in long-term
transcriptional regulation of hepatic genes associated with other disease processes.

6.2.3

Preventing
the
Developmental
Origins
Hypercholesterolemia and Glucose Intolerance

of

Hepatic differentiation in mammals begins at an early stage in utero, during which liver
has a major hematopoietic function until birth32. In rodents, the liver bud is formed
containing bipotential progenitor cells that differentiate into either hepatocytes or ductal
cells at mid-gestation32. In the last three days of gestation, a high rate of fetal hepatocyte
proliferation results in the tripling of total liver weight33. This is followed by a transition
of fetal to adult rat hepatocytes in the first week of postnatal life34. Given that there is a
high rate of neogenesis, replication and apoptosis during this neonatal period in rats 33, it
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represents a critical window for therapy designed to improving hepatic function and
proliferation. It has been previously demonstrated that the neonatal administration of
Exendin-4 (a GLP-1 analogy) in IUGR rats derived from uterine-ligated dams rescued βcell function and prevented the development of diabetes35-37. This was attributed to be
due to the restoration of expression of a key transcription factor Pdx-1, via epigenetic
mechanism induced alterations at its promoter region. In addition, Exendin-4 treatment
during this neonatal period has been demonstrated to prevent the development of hepatic
oxidative stress and insulin resistance35. These studies remarkably illustrate that neonatal
intervention can influence both pancreatic and liver development long-term. Future
studies should be aimed at investigating how we can exploit this plasticity in liver
development to correct the abnormalities that result from an adverse in utero
environment.
Attempts were made to correct the hypercholesterolemia in MPR derived IUGR offspring
by administering an LXR agonist (GW3695) from postnatal day 5 to 15 (Figure 6.1). The
LXR agonist GW3695 was chosen for these studies in MPR offspring for several reasons:
(1) restoration of proteins during neonatal life (LP3) stimulated LXR expression and
restored cholesterol homeostasis, (2) hepatic LXR expression is impaired in MPR
offspring at day 13038, (3) diminished hepatic LXR in MPR offspring also mediates their
impaired glucose tolerance36 and (4) GW3695 has been previously used in neonatal rat
studies in vivo to effectively boost LXR activity39, 40. Interestingly, a week later (postnatal
day 21), these offspring had decreased circulating LDL:HDL cholesterol ratios which
was concomitant with elevated LXR and Cyp7a1 expression41. Furthermore, this was
associated with a permissive chromatin environment as assessed by increases in the
acetylation of histone H3 [lysine 9] surrounding the LXRE of the Cyp7a1 promoter41.
Investigations to determine whether these changes are maintained in adulthood as a
consequence of this neonatal LXR are currently underway. Future studies should also
focus on determining whether this intervention will reverse the glucose impairment
observed in these offspring in adult life.
In Chapter Four it was demonstrated that a mismatched diet leads to increased ER stress
in IUGR rats. However, little is known about whether early intervention with diet or

158

drugs could alleviate ER stress and symptoms of the metabolic syndrome long-term. In
adults, a number of studies have demonstrated significant clinical implications of
therapies to improve metabolic control by alleviating ER stress. In humans, weight loss
has been associated with a decrease in ER stress markers in the adipose and liver
tissues42. Furthermore, chemical and molecular chaperones have received a lot of
attention as agents improving metabolic control and insulin sensitivity in animal models,
as well as in obese humans43-46. For instance, the chemical chaperone sodium 4phenylbutyrate (PBA), has been demonstrated to reduce ER stress induced by either
hepatocellular injury or chronic oleate exposure in mice47,

48

. In humans, oral

administration of PBA has been observed to alleviate insulin resistance and  cell
dysfunction49. Although PBA is not safe to use during pregnancy, it is routinely used in
children

for

the

treatment

of

urea

cycle

disorders

(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000219/WC500024753.pdf)50. Therefore, despite being
unsafe during pregnancy, it may prove to be an effective agent for intervention during
neonatal life of IUGR offspring. Orally active Tauroursodeoxycholic Acid (TUDCA) is
another example of chemical chaperone that has been demonstrated to improve insulin
sensitivity of the liver and skeletal muscle in animals and humans43,

46

. Interestingly,

unconjugated Ursodeoxycholic acid (UDCA) is clinically approved for the treatment of
intrahepatic cholestasis during pregnancy51-53. In addition, UDCA has been demonstrated
to reduce apoptosis in human placental explants treated with increasing levels of bile
acids54,

55

. However, the use of TUDCA for the purpose of preventing placental

insufficiency by increasing its ER folding capacity has never been investigated. In
addition, the use of PBA or TUDCA during neonatal life has not been considered in
preventing the onset of the metabolic syndrome in IUGR offspring. It is conceivable that
short-term intervention, which exploits liver plasticity during development, by
administration of chemical ER chaperones would help prevent the observed increases in
cholesterol levels and glucose intolerance in the adulthood4, 56. Studies with similarity to
the LXR agonist neonatal intervention approach are currently underway to determine if
oral administration of TUDCA (1g/Kg body weight) will prevent ER stress and rescue
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the high cholesterol levels and glucose impairment of MPR derived IUGR offspring in
adult life (Figure 6.1).
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Figure 6.1: Neonatal Drug Intervention Studies. Cholesterol and glucose homeostatic
parameters will be examined in four separate dietary regimes which include a normal
(20%) protein diet administered a vehicle (Vehicle + CONTROL) or a drug (Drug +
CONTROL) and a low (8%) protein diet during pregnancy and weaning alongside
administration of a Vehicle (Vehicle + LP2) or a drug (Drug + LP2) from postnatal day 5
to 15. Vehicle and drugs were administered intra-peritoneal (IP). Vehicle: DMSO
(50mg/kg IP). Drug: LXRα Agonist GW3695 (50mg/kg IP) or ER chaperone TUDCA
(1g/kg administered orally).
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6.2.4

Investigating Alterations in Drug Metabolism in Adulthood of
IUGR Offspring

Based on the findings presented in this thesis, IUGR offspring are more likely to be
prescribed drugs for management of metabolic risk factors. However, epidemiological
studies have not been conducted to determine if this is indeed true. In Chapter Five, a
MPR rat model was used to demonstrate that IUGR offspring have elevated activity of
important hepatic drug metabolizing Cyp enzymes in adulthood. These findings
suggested that IUGR offspring would require augmented doses of drugs in adult life in
order to exert their therapeutic effect when compared to normal birth weight offspring.
Further experimentation is required in order to validate this point. A quick indicator of
whether pharmacokinetics of a drug is altered in animals can be derived from the
zoxazolamine paralysis assay, where a decrease in duration of paralysis is related to faster
clearance of zoxazolamine57. For a more thorough and conclusive analysis,
pharmacokinetic parameters of drugs of interest need to be correlated with their
respective drug disposition molecular pathways in adult life of IUGR offspring. These
pathways mainly include Phase I and Phase II drug metabolizing enzymes, plasma
binding proteins, uptake proteins and transporters in several tissues. Moreover, it remains
to be determined whether different insults leading to IUGR would similarly impact drug
pharmacokinetic measures in adult life.

6.3

Conclusions

The impact of adverse events during development on an individual’s long-term wellbeing
is undoubtedly strong. In most cases these adverse events can be prevented from
occurring by intervention. However, there are several scenarios where adverse events
remain unnoticed or have already impacted developmental processes by the time they are
recognized. Therefore, development of biomarkers, which provide earlier identification
of impaired development would be invaluable in these situations. However, until this can
be achieved, it is imperative to increase our understanding of the underlying mechanisms
which program offspring impacted by these adverse events to an increased risk of adult
diseases. Therefore, the focus of this thesis was to investigate these mechanisms in order
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to enhance our understanding of why low birth weight offspring have increased risk of
developing the metabolic syndrome in adult life (Figure 6.2). In the first section of the
thesis, elevated cholesterol levels in low birth weight offspring were shown to be linked
to long-term repressive changes in histone modifications at the promoter of Cholesterol
7-Hydroxylase, a rate-limiting enzyme involved with cholesterol catabolism. The
second section of the thesis provided novel evidence to suggest that in addition to
epigenetic and transcriptional mechanisms underlying the ‘developmental origins of adult
disease’, activation of hepatic ER stress may mediate long-term insulin resistance and
hypercholesterolemia observed in these offspring (Figure 6.2). Moreover, these two
sections provide support to the “Predictive Adaptive Response” hypothesis, as the
impairment in hepatic cholesterol catabolism and ER stress was present exclusively in the
IUGR rat offspring which received a nutritional mismatch and displayed accelerated
growth rates in postnatal life. By understanding the role of these molecular mechanisms
in mediating these developmental abnormalities, better strategies for preventing the onset
of adult diseases can be developed. The third section of this thesis focuses on
investigating mechanisms which will enable the development of strategies for risk
management as opposed to risk prevention (Figure 6.2). Given that IUGR offspring are
more likely to be prescribed medication for management of the metabolic syndrome, the
impact of IUGR on Phase I of drug metabolizing enzymes in adulthood was investigated
in Chapter Five. The findings demonstrated that IUGR offspring when faced with a
nutritional mismatch had elevated Cy3a, Cyp2b and Cyp2b enzyme activity, suggesting
the need for augmented doses of drugs metabolized by these enzymes in order to manage
the symptoms of the metabolic syndrome in adult life. Overall, it is anticipated that the
findings presented in this thesis will lead to a better understanding of the molecular
mechanisms underlying the early programming of the liver.

163

Figure 6.2: Schematic summary of the Thesis
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